Stockwinners Market Radar for July 12, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 232.5K shares of Butterfly Network today

20:04 EDT Cathie Wood's ARK Investment bought 1.66M shares of Ginkgo Bioworks today

17:44 EDT Twitter sues Elon Musk, says company faces 'irreparable harm absent relief' - Twitter (TWTR) chairman Bret Taylor confirmed in a tweet that the company has filed a lawsuit in the Delaware Court of Chancery against Tesla (TSLA) founder Elon Musk for terminating his deal to acquire the social media giant. Taylor said the company filed the suit to "hold Elon Musk accountable to his contractual obligations." "Having mounted a public spectacle to put Twitter in play, and having proposed and then signed a seller-friendly merger agreement, Musk apparently believes that he - unlike every other party subject to Delaware contract law - is free to change his mind, trash the company, disrupt its operations, destroy stockholder value, and walk away," the suit reads. "This repudiation follows a long list of material contractual breaches by Musk that have cast a pall over Twitter and its business. Twitter brings this action to enjoin Musk from further breaches, to compel Musk to fulfill his legal obligations, and to compel consummation of the merger upon satisfaction of the few outstanding conditions." According to the filing, Twitter said it faces "irreparable harm" as a result of Musk's recent actions, adding that "swift remedial action in the form of specific performance and injunctive relief is warranted." Reference Link

17:32 EDT Osisko Gold reports preliminary Q2 deliveries of 22,240 attributable GEOs - Osisko earned approximately 22,240 attributable gold equivalent ounces, or GEOs, in the second quarter of 2022, record deliveries for the corporation since inception in 2014. Osisko had record preliminary revenues from royalties and streams of C$51.5M during the second quarter and preliminary cost of sales of C$3.7M, resulting in a record quarterly cash margin of approximately C$47.8M or approximately 93%. Osisko will provide full production and financial details with the release of its second quarter 2022 results after market close on Tuesday, August 9 followed by a conference call on Wednesday, August 10. Sandeep Singh, president and CEO of Osisko commented: "Our royalty and streaming portfolio delivered records on a number of fronts in Q2 including GEO deliveries and absolute cash margins. We continue to expect further increases in deliveries in the second half of the year as ramp-ups at Mantos and Eagle progress towards nameplate capacity. In a period of heightened volatility in the mining sector, and rising costs across all facets of the economy, our inflation protected business model continues to thrive."

17:07 EDT Fastenal announces additional 8M share repurchase program - The company said, "As of June 30, 2022, we had remaining authority to repurchase 2,200,000 shares under the July 11, 2017 authorization. On July 12, 2022, the board of directors authorized repurchases by the company of up to an additional 8,000,000 shares of its common stock. These authorizations do not have an expiration date. All share and per share information reflects the two-for-one stock split in 2019."

17:03 EDT Bit Digital reports 67.6 bitcoins earned in June - Bit Digital announced its unaudited bitcoin and Ethereum production and corporate updates for the month of June. Corporate highlights include: In June 2022, the Company earned 67.6 bitcoins and 0.0 ETHs; treasury holdings of BTC and ETH were 860.7 and 313.6, with a fair market value of approximately $17.0M and $300,000, respectively, on June 30; the Company owned 38,135 bitcoin miners and 731 Ethereum miners as of June 30 with an estimated maximum total hash rate of 2.7 EH/s and 0.3 TH/s, respectively. During the month of June, the Company continued to work with hosting partners to deploy miners. 23% of our currently-owned fleet, or 8,990 bitcoin miners representing 0.76 Exahash, was deployed in North America as of June 30.

17:01 EDT Pinnacle Financial to eliminate NSF fees for consumers - Pinnacle Financial Partners announced that Pinnacle Bank will make significant changes this summer to its overdraft services program by completely eliminating one fee, lowering another and introducing features to further reduce the total cost incurred by its clients in a single day. Effective Aug. 1, 2022, Pinnacle will: Eliminate the Non-Sufficient Funds fee for returned items for consumer accounts; Reduce the NSF returned item fee from $38 to $30 for business accounts; Reduce the Overdraft fee for paid items from $38 to $30 for consumer and business accounts; Introduce an overdraft cushion of $15 for consumers; Reduce the maximum number of Overdraft Paid Item charges per day from five to three for consumers. By reducing the fee and the number of charges consumer clients can receive in a day, the maximum possible charge per day will be reduced by more than 50 percent, from $190 to $90. Pinnacle will continue its longstanding practice of offering Overdraft Protection for no charge. This service gives clients who opt in the ability to link accounts so funds can be transferred automatically to avoid an overdraft.

16:51 EDT Four Corners Property Trust acquires Caliber Collision property for $1.1M - Four Corners Property Trust announced the acquisition of a Caliber Collision property for $1.1M. The property is located in a corridor in Michigan and is corporate-operated under a net lease with approximately nine years of term remaining. The transaction was priced at a 6.6% cap rate, exclusive of transaction costs.

16:49 EDT SQZ Biotechnologies announces publication of review on APCs - SQZ Biotechnologies announced the publication of a technical review examining the ability of SQZ Antigen Presenting Cells, or APCs, to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO's Immuno-Oncology and Technology, or IOTECH, journal, the review further explores the advantages of the company's Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities. The Cell Squeeze engineering method has compelling features compared to viral or electroporation approaches across a number of categories, including cell perturbation, scalability, cell types, cargo types, targeting, dosage control, and cost per dose. SQZ's approach has demonstrated preclinically dramatic improvements in potential CD8 T cell activation as well as synergy with next generation immuno-oncology drugs such as PD-1 IL2v. SQZ clinical candidates experienced an average vein-to-vein time of roughly one week, faster than most other therapeutic approaches for delivering sterile cell therapy.

16:44 EDT Officer of Keurig Dr Pepper Milikin purchases $469K in company shares - Officer of Keurig Dr Pepper Maurice Milikin disclosed in a filing that he had purchased 12,979 shares of company stock at $36.17 per share on July 11, for a total transaction amount of $469,450.

16:34 EDT Aviat sends letter to Ceragon shareholders regarding acquisition proposal - Aviat Networks (AVNW) issued an open letter to shareholders of Ceragon Networks (CRNT) encouraging them to urge the Ceragon board of directors to seriously consider Aviat's acquisition proposal. The letter said, "As the third largest shareholder of Ceragon, we are concerned about the Company's continued poor performance and prospects, and based on the calls we have received since publicly announcing our proposal to acquire Ceragon on June 27th (U.S.) / June 28th (Israel), we believe that many of you may share our concerns. During the last five years, Ceragon stock has declined 12%, while the Russell 2000 has appreciated by 33% in the same timeframe. Ceragon is therefore underperforming the market by a differential of 45 percentage points. The Company's gross margin has declined from 34% in calendar year 2019 to 30% over the last twelve months, during which time Ceragon has generated negative free cash flow of $42 million. The strategy of the current leadership team simply is not working. While Ceragon leaders say things are going to turn around, much of its forecasted improvement is based on the rollout of a next generation chip that has been repeatedly delayed, first under the leadership of the Company's former CEO Ira Palti, who served in the position until July 2021, and now under his successor, Doron Arazi. As CEO, Mr. Palti underestimated the impact of supply chain disruptions, mismanaged the chip development process, and miscalculated the anticipated timeline of the product rollout. Specifically, on August 2, 2020, Mr. Palti told shareholders that the estimated time from chip development to manufacturing to the next generation product rollout would be around 12 months, but on February 8, 2021, he revised this timeline to 18 months. The view of the current management team is that the chip will be ready by the end of this year, which is already well over a year behind schedule. Given the supply challenges in the chip space, which the Company has itself noted may cause further delays, we see no reason to believe this product won't continue to slip in its delivery to the market. We believe the delay is primarily the result of Ceragon attempting to reach outside its area of competency to develop a chip when it would be faster and more efficient to partner with a company that solely develops chips and can execute immediately. Thus, when Ceragon's new chip is eventually rolled out, we believe it will already lag the market in many of its performance attributes. Mr. Palti would like you to believe that there is no competitive alternative to spending two or more years developing a chip in-house, but this is wrong. In contrast, Aviat partnered with an expert to create just such an alternative. Aviat's next generation System on Chip (developed in partnership with MaxLinear) will be a more capable commercial alternative based on a newer generation of technology than Ceragon's chip, enabling network OEMs and operators to deliver ultra-high-capacity payloads, over longer distances, with the lowest possible total cost of ownership. We believe Ceragon's chip will consume more power and create cost, system design, and supply chain challenges. This type of chip problem could require a redesign at a different node to achieve competitiveness, leaving Ceragon with a technological deficit and additional expense over the long-term. Because of poor decisions and execution, we fear that Ceragon's standalone prospects are diminished, and that its underperformance will continue unless the Board takes action. To date, unfortunately, the path Ceragon's Board has chosen is inaction. The architect of the failed strategy, Mr. Palti, now holds a seat on the Board of Directors, and we believe his presence will hinder any efforts to fix the mistakes he committed, and instead continue to foster a culture of underperformance. We recognize that as the new CEO, Mr. Arazi has been put in a very difficult position, because Mr. Palti's continued participation on the Board undermines any actions that Mr. Arazi could take to correct Mr. Palti's mistakes. By his presence, Mr. Palti has wedded the Board to its failed strategy, and he has publicly expressed that Ceragon is wholly committed to seeing this strategy through, making it very difficult for Mr. Arazi to propose a change in strategy. This is one of many reasons why we are proposing to remove Mr. Palti from the Ceragon Board and replace him and other certain directors who lack sufficient independence to act in the best interest of shareholders with new, highly-qualified independent directors who can objectively evaluate all strategic proposals. You deserve a Board that has the independence and the judgment to do the right thing for shareholders. Aviat sought repeatedly to negotiate a transaction with Ceragon that could provide shareholders with certain and immediate value, would solve Ceragon's chip issues, and offers a plan to leverage Ceragon capabilities beyond microwave backhaul. Instead, your Board members dug in their heels, resorting to delay tactics that seem intended to keep their Board seats and jobs but deliver no value to shareholders. They continue to ask you to patiently endure quarter after quarter of poor results, delays, and unfulfilled promises. In the weeks since we first made our current offer to acquire Ceragon in April, the Company's stock price has dropped sharply (until it rebounded in response to our public proposal last month), which demonstrates that you, our fellow shareholders, are running out of patience..."

16:31 EDT Mercury Systems awarded $56M contract by leading defense prime contractor - Mercury Systems announced it received a $56M contract award from a leading defense prime contractor to facilitate the rapid data processing requirements for a defense radar application. The award was received in the Company's Q4 and is expected to be delivered over the next several quarters. Advanced radar systems, equipped with the processing power of Mercury's rugged servers, sort and analyze immense amounts of sensor data at the edge to enable rapid and reliable situational awareness and early warning for defense platforms, weapons systems and their crews.

16:21 EDT Siga announces approximately $28M of procurement orders for for oral TPOXX - SIGA Technologies announced approximately $28M of procurement orders for oral TPOXX, tecovirimat, including approximately $2M for initial procurement by two new international jurisdictions and approximately $26M for procurement by Canada, of which approximately $22M is being procured by the Public Health Agency of Canada PHAC and approximately $4M is being procured by the Canadian Department of National Defence DND under existing contracts. One of the new jurisdictions is in Europe, and the other new jurisdiction is in the Asia Pacific region. In combination with the approximately $13M PHAC order that was previously disclosed on the last investor call, PHAC and DND have ordered approximately $39M of oral TPOXX, tecovirimat, this year. The current order includes an approximate increase of $9M to the existing PHAC procurement contract. "The increase over the last two months in international orders of oral TPOXX reflects an initial public health reaction to the evolving monkeypox outbreak," said Phil Gomez, CEO of SIGA. "SIGA continues to receive a large number of ongoing inquiries about accessing oral TPOXX. We believe these new orders and the ongoing inquiries highlight the overall importance of health security preparedness, and that by increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared for the outbreak risks of smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses and make sure that patients are able to access treatment."

16:20 EDT Artisan Partners reports June AUM of $130.5B - Artisan Partners reported that its preliminary assets under management, or AUM, as of June 30 totaled $130.5B. Artisan Funds and Artisan Global Funds accounted for $63B of total firm AUM, while separate accounts and other AUM1 accounted for $67.5B.

16:19 EDT Innovative Solutions names Michael Linacre as CFO - Innovative Solutions & Support "announces the retirement of Relland M. Winand as the company's CFO, effective July 15, 2022, and that Dr. Shahram Askarpour, the company's CEO, has appointed, and the Board of Directors has approved the appointment of, Michael Linacre as the company's new Chief Financial Officer following Mr. Winand's retirement. Prior to joining IS&S, Mr. Linacre, worked as a public accountant at KPMG LLP."

16:17 EDT Geospace awarded $4M shallow water ocean bottom node rental contract - Geospace Technologies Corporation announced a $4M rental contract with an international marine geophysical services provider who will rent OBX-750E seabed ocean bottom wireless seismic data acquisition nodes for a shallow offshore seismic survey. "During our recent exhibition at the European Association of Geoscientists and Engineers in Madrid, we experienced a significant increase in discussions surrounding the use of our wireless ocean bottom node products for both deep and shallow water applications," said Walter R. Wheeler, President and CEO, Geospace Technologies. "This follows the announcements in our prior quarter of OBX related commerce that included a $10M sale and $7M in rental contracts. This contract provides further evidence of increased activity in offshore markets where our versatile ocean bottom node products can provide the high-quality data needed to reliably make critical exploration decisions."

16:17 EDT Invesco reports preliminary AUM $1.39T as of June 30 - Invesco reported preliminary month-end assets under management of $1.39T, a decrease of 4.2% versus previous month-end. The firm experienced net long-term outflows of $3.9B in the month. Non-management fee earning net inflows were $0.7B and money market net inflows were $15B. AUM was negatively impacted by unfavorable market returns which decreased AUM by $68B. Reinvested distributions increased AUM by $1.6B and FX decreased AUM by $6.9B. Preliminary average total AUM for the quarter through June 30 were $1.457T, and preliminary average active AUM for the quarter through June 30 were $989.2B.

16:12 EDT Golub Capital reports Q3 $449.6M in new middle-market investment commitments - Golub Capital BDC announced that it originated $449.6M in new middle-market investment commitments during the three months ended June 30. Approximately 93% of the new middle-market investment commitments were one stop loans, 2% were senior secured loans and 5% were equity and other securities. Of the new middle-market investment commitments, $350.0M funded at close. Total investments at fair value are estimated to have increased by approximately 3.5%, or $187.5M, during the three months ended June 30 after factoring in debt repayments, sales of securities, net fundings on revolvers and net change in unrealized gains.

16:10 EDT Root announces partnerships with two NFL teams - Root, the parent company of Root Insurance, announced partnerships with two National Football League teams and one Major League Baseball team. Root is now the official insurance partner of the Denver Broncos, Cleveland Browns, and additionally is a sponsor to the Colorado Rockies. Root's name, logo, and advertisements will be integrated into the teams' media, game-day graphics, and sponsored content. These new sports sponsorships are in addition to the partnership with NASCAR team 23XI and driver Bubba Wallace. Root has sponsored 23XI since 2021.

16:08 EDT Good Times reports Q3 Good Times brand SSS up 1.6% y/y - Good Times Restaurants announced that same store sales for its third quarter ended June 28, 2022 increased 1.6% for its Good Times brand from the same prior year quarter and increased 5.3% for its Bad Daddy's brand from the same prior year quarter. Average weekly sales during the 2022 third quarter among restaurants open for at least 18 months were $30,411 for the company's Good Times restaurants and $52,745 for the company's Bad Daddy's restaurants. Ryan Zink, Chief Executive Officer, said, "It is exciting to report positive comparable sales at both concepts, which we believe demonstrates the strength of our brands. During the quarter we completed the installation of new digital menu boards at one third of our company-owned Good Times and expect to complete the remainder of our restaurants by early October. Additionally, we are well into the process of permitting and construction of new signage at Good Times and expect installation at between six and eight restaurants by the end of the fiscal year and installation at all company-owned restaurants by the end of fiscal 2023. We also continue to refine and innovate our mobile app, providing a convenient platform for our Good Times guests. These improvements are key to our commitment to modernize and revitalize our iconic Colorado brand."

16:07 EDT Desktop Metal CFO James Haley to leave the company - Desktop Metal "announced that James Haley will be transitioning from his role as CFO of the Company to pursue other interests. In order to ensure a smooth transition, Haley will remain in his current role through the earlier of December 31, 2022 or the date a new CFO begins employment, and he will serve in an advisory role for a period thereafter. Desktop Metal has retained a leading executive search firm to assist in a thorough and thoughtful search for a successor."

16:06 EDT Agios names Brian Goff CEO, Jackie Fouse transition to role of chair of board - Agios Pharmaceuticals announced that effective August 8, Jackie Fouse, Ph.D., will transition to the role of chair of the board of directors and Brian Goff will assume the role of chief executive officer. Mr. Goff will also serve as a member of Agios' board of directors. Current chairman, David Schenkein, M.D., will remain on the board as a director."Throughout our history, Agios has engaged in deliberate and thoughtful long-term planning to drive positive impact for our people and patients. The team's consistent execution - reflected in the divestiture of our oncology portfolio, the approval of our first genetically defined disease medicine and the initiation of pivotal trials in thalassemia and sickle cell disease - put Agios in a position of strength and great promise for the future," said Dr. Fouse. "The time is right to evolve our leadership and deepen our genetically defined disease skill set to further drive our ability to develop life-changing treatments. Brian's strong track record of leading rare disease product launches to drive their impact for patients, building and scaling companies' rare disease capabilities and leading high-performing, diverse teams with strong cultures make him the right next leader for Agios. I look forward to working with him closely as he transitions into his new role and as I continue my commitment to Agios as chair of the board." "

16:06 EDT Starry reports Q2 Homes Serviceable up 19.6% y/y at 5.7M - The company states: "As of the end of the second quarter, homes serviceable were 5.7 million, an increase of 19.6 % year-over-year. The growth in homes serviceable was due to network improvements and expansion in existing markets. As of the end of the second quarter, customer relationships were 80,950, an increase of 69.4% year-over-year. The net additions in the quarter were a record 9,703. Starry saw growth in customer relationships in each of its six markets during the quarter. The Company increased penetration by a record 42 bps year-over-year to 1.43% by focusing sales and marketing efforts primarily on multiple dwelling units where Starry equipment had previously been installed."

15:46 EDT Table Trac installs CasinoTrac casino management system at Lucky Strike Casino - Table Trac announced that the Lucky Strike Casino in Nevada will soon have Table Trac's CasinoTrac casino management system installed. Stillwater Gaming owns and operates multiple casino properties located in Carson Valley, Churchill County and Lyon County all in Nevada. These locations feature slot machines as well as entertainment, hotels, bars and restaurants.

15:35 EDT Block says Hannon Armstrong accounting 'manipulation' not illegal, but 'extreme' - Carson Block of Muddy Waters, who announced earlier this morning that his firm is short Hannon Armstrong Sustainable Infrastructure Capital, is being interviewed on CNBC regarding his short thesis.

14:30 EDT Micron expects DRAM production output loss from power disruption - Micron Technology reported last night that it experienced a prolonged power disruption at its Hiroshima DRAM manufacturing facility on Friday, July 8, due to inclement weather in the area. "All Micron team members are safe. The loss of power prompted the implementation of factory shutdown protocols. Operations have resumed at reduced levels and will continue to ramp over the next week. Micron is assessing the wafers in process at the time of the incident to determine whether they will meet the company's stringent quality standards," the company said in a statement. Micron expects production output loss and associated cost impact from both productivity and wafer scrap across its fiscal Q4 and fiscal Q1. "Micron is currently assessing the impact to near-term supply and is working to utilize existing inventory and its remaining DRAM factory network to meet customers' critical requirements. Micron will update its customers directly as appropriate," it added. Reference Link

13:58 EDT Konecranes lowers FY22 financial guidance - "Although demand environment has remained good, global component and material availability and other supply chain issues as well as COVID-19 related challenges have continued to impact Konecranes' delivery capability in the second quarter. These issues are expected to continue, and as a result, Konecranes lowers full-year 2022 guidance. The updated financial guidance for 2022: Konecranes expects net sales to remain on the same level or to increase in full-year 2022 compared to 2021. Konecranes expects the adjusted EBITA margin to remain on the same level or to decrease in full-year 2022 compared to 2021. The previous financial guidance for 2022: Konecranes expects net sales to increase in full-year 2022 compared to 2021. Konecranes expects the full-year 2022 adjusted EBITA margin to improve from 2021. In 2021, Konecranes net sales totaled EUR 3,185.7M and adjusted EBITA margin was 9.8%," the company said in a statement. Reference Link

13:08 EDT Kaleyra trading halted, news pending

13:01 EDT Seclore enters partnership with TD Synnex - Seclore announced a new partnership with TD SYNNEX. This partnership enables enterprises to access complete solutions to solve their data protection challenges.The joint solution provides real-time tracking and visibility of both authorized and unauthorized activity on the data so the enterprise can learn, identify suspicious behavior, evolve data security policies, take immediate action on security permissions, and even complete removal to prevent data loss.

12:49 EDT Unity Bancorp added to membership of U.S. Small-Cap Russell 2000 Index - Unity Bancorp, parent company of Unity Bank, was added as a member of the U.S. small-cap Russell 2000 Index, widely regarded as a bellwether of the U.S. economy due to its focus on American small businesses. The Russell 2000 membership became effective on June 27th, as part of the 2022 Russell indexes reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. Unity's stock also was automatically added to the appropriate growth and value indexes. Unity holds approximately $2.1B in assets and $1.8B in deposits. "We are extremely pleased to have been added as a member of the Russell 2000 Index as it illustrates Unity's continued financial strength and performance," said Unity Bank President & CEO James A. Hughes. "We measure the bank's performance on both financial metrics and Unity's ability to come together with our customers to fulfill their needs and deliver extraordinary service. The bank's mission is to grow with the communities we serve and the dedication of Unity's employees and the loyalty and trust of our customers help the bank achieve those goals everyday."

12:33 EDT Coinbase CEO says 'focusing on driving more efficiency' - Brian Armstrong, CEO and Co-founder of Coinbase, stated in a post to the company's blog: "Great companies maintain their insurgent mindset, for fear of becoming complacent and irrelevant over time. That's why we're focusing on driving more efficiency at Coinbase. After 18 months of ~200% y/y employee growth, many of our internal tools and organizing principles have started to strain or break. So we've been digging in to identify the set of changes we need to make to help us succeed at this new scale. The first step was significantly slowing our growth, and making the difficult decision to reduce the size of our current team, which we announced last month. Moving forward, we'll keep looking for ways to make Coinbase more efficient, and to get back to the mindset and approach that made us successful. I believe that these steps will carry us forward... Coinbase's success has always been rooted in an ability to operate efficiently with a startup mindset. Now, as we adjust to our new scale, we need to get back to the things that made us successful - to drive more efficiency and shake off the complacency that can creep into a bigger company. We need to empower our leaders to make decisions, and our teams to deliver great products to customers. It won't be easy, and we'll need to keep adjusting. But we got this far, and I'm confident that if we make smart decisions now, it will only be the beginning." Reference Link

12:03 EDT Peoples Trust Company chooses CGI All Payments to digitize payments system - CGI announced that Peoples Trust Company has selected CGI All Payments to provide the capabilities the company needs to directly participate in Canada's Automated Clearing Settlement System. ACSS is the system through which Canadian cheques and electronic payments are cleared and settled. In June 2022, PTC became the first new direct participant connecting to ACSS in nearly 40 years. Further, PTC will use CGI All Payments, a proprietary, market-leading, cloud-based platform, to modernize and digitize its payments systems and expand its payment offerings for customers.

12:00 EDT E2open falls -17.0% - E2open is down -17.0%, or -$1.27 to $6.25.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 8.4% - ProShares UltraShort Bloomberg Natural Gas is up 8.4%, or $2.33 to $30.02.

12:00 EDT Herbalife Nutrition rises 16.3% - Herbalife Nutrition is up 16.3%, or $3.21 to $22.92.

11:12 EDT Richardson Electronics enters distribution agreement with Altum RF - Richardson Electronics announces a global sales distribution agreement with Altum RF. With amplifiers, switches and other products working up to 100GHz, Altum will further expand Richardson Electronics' portfolio to support continually rising frequencies in the market, including 5G/6G, SATCOM, test, and defense applications. Inspired by leading experts in the RF/microwave industry, Altum RF transforms how partnerships work to develop high-performance products with a focus on excellent technical support and customer service.

10:47 EDT AWS announces general availability of AWS Cloud WAN - Amazon Web Services, or AWS, an Amazon.com company, announced the general availability of AWS Cloud WAN, which it calls "a new managed wide area network service that connects on-premises data centers, colocation facilities, branch offices, and cloud resources to simplify operating a global network." AWS said: "Using a central management dashboard built into AWS Cloud WAN, customers can define their network configuration, view the health of their global network, and automate routine configuration and security tasks. With AWS Cloud WAN, enterprises can access the AWS global network to build a single, unified network for their organization to improve network health, performance, and security."

10:37 EDT Getaround brings contactless carsharing to New York City - Getaround announced that Peer-to-Peer Car Sharing Program Act will now allow the platform to be widely available for all New Yorkers. While Getaround has been active in New York since 2019, state laws required individuals to have commercial insurance to share their vehicles, making widespread use of the platform impractical for the general public. However, thanks to years of advocacy and cooperation with policymakers, the Peer-to-Peer Car Sharing Program Act now allows Getaround to provide platform insurance to cover trips within New York at no extra cost to the user, making it an accessible and sustainable transportation solution.

10:28 EDT Hoth Therapeutics announces proof-of-concept data for HT-ALZ - Hoth Therapeutics announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease. The chronic dosing experiments, conducted by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine, included a battery of behavioral assessments after greater than5 weeks oral treatment with HT-ALZ. These behavioral assessments are considered the gold standard for predictive cognitive, learning, and memory improvement potential for AD therapeutics. All of the behavioral tests performed after greater than5 weeks treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild type animals. Overall, the results support the therapeutic potential of HT-ALZ to provide cognitive improvement as an AD therapeutic. Other behavioral assessments performed at earlier treatment periods with HT-ALZ did not show a significant improvement compared to vehicle treated animals, however, were trending in a positive predictive manner towards improvement; this data suggests a time-dependent improvement after initiation of HT-ALZ treatment consistent with other AD therapeutics1. These other behavioral assessments are currently being repeated after longer HT-ALZ dosing periods. AD is a neurodegenerative disease that is characterized by aggregates of amyloid beta plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia. Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Abeta in the brain interstitial fluid, using an established Alzheimer's Disease mouse model. The initial data from these studies shows a significant decrease in Abeta in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Abeta levels. Further work is underway to determine how HT-ALZ impacts Abeta pathology following chronic treatment. Future research studies to be conducted by Dr. Cirrito and Dr. Yuede will investigate the effect of HT-ALZ on memory, anxiety, and executive function in the APP/PS1+/- mice model after chronic dosing with HT-ALZ at 4 different dose levels to determine if there is a dose-dependent response for selection of the human equivalent dose for future clinical trials with HT-ALZ.

10:24 EDT Muddy Waters announces short position in Hannon Armstrong

10:19 EDT Hannon Armstrong weakness attributed to short call from Muddy Waters - Shares of Hannon Armstrong Sustainable Infrastructure Capital are down $2.19, or 6%, to $34.14 in morning trading and the weakness is being attributed to a short call being discussed on Muddy Waters' Zer0es TV. Reference Link

10:11 EDT Sharps Compliance to be acquired by Aurora Capital affiliate for $8.75 per share

10:08 EDT Lam Research, Entegris, Gelest partner for EUV dry resist technology ecosystem - Lam Research Corp. (LRCX), Entegris (ENTG), and Gelest, Inc, a Mitsubishi Chemical Group company (MTLHF), announced a strategic collaboration that will provide semiconductor manufacturers worldwide with reliable access to precursor chemicals for Lam's breakthrough dry photoresist technology for extreme ultraviolet lithography, an innovative approach used in the production of next-generation semiconductors. The parties will work together on EUV dry resist technology research and development for future device generations of logic and DRAM products that will help enable everything from machine learning and artificial intelligence to mobile devices. A robust supply chain for process chemicals is critical to EUV dry resist technology integration into high-volume manufacturing. This new long-term collaboration further broadens the growing ecosystem for dry resist technology and will provide dual-source supply from semiconductor material leaders with provisions for continuity of delivery in all global markets. In addition, Lam, Entegris, and Gelest will work together to accelerate the development of future cost-effective EUV dry resist solutions for high numerical aperture EUV patterning. High-NA EUV is widely seen as the patterning technology that will be required for continued device scaling and advancement of semiconductor technology over the coming decades. Dry resist provides the high etch resistance and tunable thickness scaling of deposition and development necessary to support high-NA EUV's reduced depth of focus requirements.

10:03 EDT Jabil, IdentifySensors Biologics partner for digital diagnostic platform - IdentifySensors Biologics has partnered with Jabil to develop processes for reliable robust manufacturing of portable devices that rapidly detect a wide range of infections at the molecular level with accuracy that is superior to PCR testing. The small portable devices, branded Check4, consist of two main parts: a multiple-use electronic reader about the size of a cell phone; and single-use test cartridges that detect as many as four separate infections simultaneously. For example, a single cartridge can detect COVID, Influenza A, Influenza B and RSV - all from a single saliva sample. Results appear in minutes on a user's cell phone, at home or on the go.

10:00 EDT Universal Compression falls -8.7% - Universal Compression is down -8.7%, or -$3.39 to $35.69.

10:00 EDT E2open falls -11.6% - E2open is down -11.6%, or -87c to $6.65.

10:00 EDT Scor ADR rises 8.4% - Scor ADR is up 8.4%, or $1.98 to $25.48.

09:56 EDT Sharps Compliance trading halted, news pending

09:51 EDT Kaspien Holdings Inc trading resumes

09:47 EDT E2open falls -7.4% - E2open is down -7.4%, or -56c to $6.96.

09:47 EDT Glaukos rises 7.8% - Glaukos is up 7.8%, or $3.66 to $50.72.

09:47 EDT SIGNA Sports United rises 15.6% - SIGNA Sports United is up 15.6%, or 77c to $5.70.

09:44 EDT Greenwich LifeSciences Inc trading resumes

09:36 EDT SaverOne 2014 appoints Israel Eybi as Chief Marketing Officer - SaverOne 2014 announced the appointment of Israel Eybi as SaverOne's Chief Marketing and Sales Officer. Prior to SaverOne, Eybi was Business Development Executive at 4Cast during 2021 and Chief Customer Officer at Israel's main telephony group, Bezeq from 2019 to 2021, the company stated.

09:34 EDT Greenwich LifeSciences Inc trading halted, volatility trading pause

09:32 EDT MyMD Pharmaceuticals collaborates with Bascom Palmer Eye Institute - MyMD Pharmaceuticals announced that it has entered into a material transfer agreement with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1 as a potential treatment for traumatic optic neuropathy. The project is fully funded by Bascom Palmer Eye Institute.

09:30 EDT Cinedigm sees $7.5M annual cost savings following streamlining this year - Cinedigm released comments by Chairman and CEO Chris McGurk highlighting the Company's positive business momentum, growth trajectory, financial targets and plan for sustainable profitability and positive cash flow by the fiscal fourth quarter, ending March 31, 2023. The letter read in part, "I believe it is important, following the recent release of Cinedigm's outstanding business and financial performance for the quarter and fiscal year ended March 31, 2022, to reach out to our shareholders to underscore that our go-forward growth prospects and business momentum are more positive than ever and that the Company is rapidly moving to a position of sustainable profitability and positive cash flow by the fourth quarter of this current fiscal year, ending March 31, 2023. I want to reiterate how our vastly increased scale, following seven key roll-up acquisitions and a multi-year investment program in technology, streaming channels and content, has enabled Cinedigm to become an increasingly impactful player in the streaming content and technology business, and has set the stage for the Company to launch four key internal growth initiatives. We expect these initiatives, along with international business expansion, to generate incremental annual high margin revenues of over $50 million at steady state, with only minor added investment. In addition, the synergies and scale benefits from recently acquired assets will enable us to dramatically streamline our cost structure. We expect to generate at least $7.5 million in annual cost savings when we complete our streamlining this year...To conclude, while the markets have been extremely challenging over the last several months, Cinedigm is in the strongest position ever to continue to build a high growth, profitable and cash flow positive business that should reward shareholders who have a long-term perspective with significant growth in value. With the tremendous results we reported this last fiscal year, the continued rapid growth in our streaming revenues and metrics that continue in this current first fiscal quarter, and with our four new high-margin internal initiatives rolling out, the Cinedigm team is more confident than ever that our business and financial momentum will continue in fiscal 2023 and for years to come as we work toward our goal of sustained profitability this year and achieving a $150 million revenue in 2-4 years' time."

09:28 EDT Wildpack reports June equivalent standard 12 oz can throughput of 18.7M - Wildpack Beverage announces June production. June equivalent standard 12-ounce can throughput was 18.7 million, a month-over-month increase of 18%. Wildpack's throughput results, which include cans and can equivalents, are trending towards profitability and positive cashflow. In the month, can decorating, can filling and sleeve printing operations all achieved new record throughput. Can decorating achieved 6.4 million units, a 98% MoM improvement, can filling achieved 1.4 million units, a 17% MoM improvement, and printing operations continued to improve, with 4.0 million units produced along with several single day records. Can brokering increased 18% MoM while the add on business of packaging sales decreased 47% MoM due to customers drawing down their existing packaging inventory. Wildpack's total sales orders for the month of June set a record of 153, a 26% MoM improvement, with 24 new customer conversions. As reported in Wildpack's first quarter financials, plant utilization was 15.8%, whereas in June this dramatically improved to 37.8%, an increase of 139% from first quarter averages, and a 76% MoM improvement, all trending toward our operational goals. Production line yields have remained above 90% for the duration of the month despite the increase in utilization. Wildpack's Board of Directors has approved the grant of an aggregate of 852,000 common share options to its officers, pursuant to the Company's omnibus incentive plan at an exercise price of C$0.55. Each Option shall vest, per the agreement, upon achievement of certain milestones. If the milestones are not met, the applicable Options will be null and void. Each Option represents the right to receive, once vested, one common share of the Company and is exercisable until December 31, 2025. The Company also announced the Board has approved the grant of an aggregate of 1,573,124 restricted share units to certain of its key employees and directors pursuant to the Plan. Each RSU shall vest, per the agreement, over various periods qualified by time and/or the achievement of certain milestones. If the milestones are not met, the applicable RSUs will be null and void. Each RSU represents the right to receive, once vested, one common share of the Company. All Options and RSUs were granted pursuant and subject to the terms of the Plan, the applicable grant agreement, and the requirements of the TSX Venture Exchange.

09:26 EDT Nordic American Tankers seeing 'strong improvement' for vessels - The company said, "We are seeing a strong improvement for our vessels. The fixtures also reflect waiting time. Our operating costs are about USD 7,500/day. The market improvement is clear: 8th July: Vessel fixed to Chinese interests for a voyage from Libya to China. Time Charter Equivalent about USD 32,500 over 52 days. 7th July 2022: Vessel fixed to European interest for a voyage from Mediterranean to Singapore. The TCE is about USD 32,700 over 40 days. 5th July 2022: Vessel fixed to a major for a voyage from South America to US East Coast. TCE about USD 51,000 over 20 days. 29th June 2022: A vessel fixed to European major for voyage from West Africa to Spain. TCE about USD 30,000 over 33 days. 21st June 2022: A vessel fixed to European major for a voyage from East Coast Mexico to Continent. TCE about USD 35,500. 6th June 2022: A vessel fixed to a major for a voyage from West Africa to Trieste. TCE about USD 24,000 over 39 days."

09:23 EDT Zedge launches multiple localized versions of Emojipedia - Zedge announced that, in anticipation of World Emoji Day, Emojipedia is now available in localized versions featuring Spanish, French, German, Italian and Portuguese.

09:20 EDT Principal Solar provides operational update on partnership with Aramis - Principal Solar provided an operational update regarding its recent partnership with Aramis. The two companies entered into a partnership agreement in June of 2022 for the purpose of reworking eight wells in Caldwell County, Texas. "As of July 12, 2022, seven of the eight wells we're reworking with Aramis have been brought up to stripper production status*," said Anthony Lerner, Director and Chief Operating Officer of Principal Solar. "We anticipate all eight wells will be returned to production, at which point we intend to work with Aramis to identify additional wells with production potential in the Luling and Central Texas areas."

09:18 EDT Yield10 Bioscience changes name of Canadian subsidiary to Yield10 Oilseeds - Yield10 Bioscience announced the name change of its wholly-owned Canadian subsidiary to Yield10 Oilseeds from Metabolix Oilseeds, Inc. effective July 12, 2022. This name change creates an alignment of Yield10 Bioscience's Canadian subsidiary with the branding associated with the Yield10 Bioscience business, which is focused on innovation in oilseed crops to develop crop-based solutions to address global food security, climate change and plastic waste in the environment. "By rebranding our Canadian subsidiary to Yield10 Oilseeds Inc. we are unifying our business under the Yield10 brand," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield10 Bioscience. "We are taking this step now as we are placing an emphasis within our business on grower outreach and engagement to begin ramping up Camelina acres for the production of feedstock oil targeting the biofuels market and protein meal for animal feed. As we move forward, the Yield10 Oilseeds brand will signify our commitment to innovation and excellence in oilseed crops as we bring our elite Camelina varieties to market."

09:17 EDT Tenable Holdings adds Nessus Expert to portfolio of assessment solutions - Tenable announced the addition of Nessus Expert to its portfolio of trusted vulnerability assessment solutions, giving security consultants, pen testers and security practitioners extended external capabilities and expanded visibility into cloud native environments.

09:16 EDT SkyWater Technology announces DOD funding for OT agreement option - SkyWater Technology announced the Department of Defense, or DOD, is funding a $27M Other Transactional, or OT, agreement option to further develop intellectual property for its 90 nm Strategic Rad-Hard by Process FDSOI technology platform. This is the latest agreement between SkyWater and the DOD to ensure a reliable and trusted source of U.S.-made chips for use in strategic defense and space applications. This is another step in SkyWater's RH90 technology roadmap and is part of the previously announced up to $170M investment in SkyWater by the DOD to broaden onshore production capabilities for strategic rad-hard electronics. The DOD recently determined that SkyWater has successfully completed the base prototype project.

09:14 EDT Eneti announces Scorpio purchased 153,825 shares at $5.25 per share - Eneti announced that Scorpio, a related party, has purchased 153,825 common shares of the Company at an average price of $5.25 per share in the open market. The Company currently has 40,738,704 common shares outstanding, of which SHL and its affiliates own 9,077,984 or 22.28%.

09:12 EDT Brilliant Earth launches Reflections Collection - Brilliant Earth Group announced the launch of the Reflections Collection, an exclusive collection of bridal and fine jewelry celebrating the harmony of mirrored designs found in nature. The 21-piece collection is crafted for modern consumers looking for distinct styles with meaningful purpose. Consisting of seven engagement rings, six wedding bands and eight fine jewelry pieces, the collection showcases the beauty of nature's symmetry, patterns and curved lines through thoughtful design. Styles from Brilliant Earth's Reflections collection range from $795 to $12,000 and will be available to purchase exclusively at all Brilliant Earth Showrooms and online at www.BrilliantEarth.com, beginning July 7, 2022.

09:09 EDT Digital Ally awarded notable contract for body-worn cameras - Digital Ally announced it has received an order for 176 FirstVu Pro body cameras from the Kansas Department of Wildlife and Parks. The body cameras will be deployed for the agency's law enforcement officers throughout the state. "We're very excited to play a part in helping the Kansas Department of Wildlife and Parks keep its enforcement officers and the general community as safe as possible," said Stan Ross, CEO of Digital Ally, adding, "The FirstVu Pro is a truly innovative technology with industry-leading features that are critical for safety and security."

09:08 EDT CohBar appoints Tozzo to board of directors - CohBar announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings research and development experience at both established pharmaceutical and innovative biotechnology companies. Dr. Tozzo is currently Chief Scientific Officer at Avilar Therapeutics.

09:07 EDT RCI Hospitality reports Q3 Nightclubs and Bombshells restaurants sales $70.1M - RCI Hospitality Holdings reported sales for its Nightclubs and Bombshells restaurants of $70.1M for the Q3. Sales do not include non-core operations and are preliminary and subject to final closing. Full Q3 financial results are expected by August 9. RCI also announced it bought back 168,069 shares in 3Q22 totaling $9.2M. "We're pleased revenues hit the higher end of our target annual run rate of $260M-$280M," Langan said. "The third quarter was the first period since 1Q20 not affected by COVID. It also benefitted from the full integration of our 1Q22 club acquisitions. Bombshells faced comparisons to an unusually strong year-ago quarter, when it was one of the few bar and restaurant chains open in Texas, with little competition due to the state of COVID at the time. Otherwise, Bombshells saw typical seasonal trends. Armed with high cash balances from strong sales, we took advantage of market conditions to repurchase 1.78% of shares outstanding since March 31 and we ended the quarter with $37.5M cash and cash equivalents."

09:06 EDT Coupa Software opens three new offices in Latin America - Coupa Software announced the opening of three new offices this month in Latin America - Mexico City, Sao Paulo, and Bogota - the first offices for the company in the region. The new offices will be located in the main cities of Brazil, Mexico, and Colombia, the three largest countries in Latin America by population and which share some of the highest GDPs in the region. The new offices build on the investment and momentum of Coupa in the LATAM market and will allow Coupa to have a greater impact on employees and customers.

09:05 EDT Blue Hat Interactive announces registered direct offering - Blue Hat Interactive Entertainment Technology announces that it entered into two Securities Purchase Agreements with two accredited investors for the total sale of 1,000,000 ordinary shares, par value $0.01 per share, of the Company at a price of $3.60 per share. The total Offering are for $3,600,000. The Company intends to use the net cash proceeds from the Offering for working capital and general corporate purposes. The first tranche of the Offering in the amount of $1,440,000 is expected to close on or around July 13, 2022 and the second tranche of the Offering for the remaining $2,160,000 is expected to close thereafter in July 2022.

09:05 EDT Pulmatrix announces dosing of first patients in Phase 1 trial of PUR3100 - Pulmatrix announced the dosing of the first five subjects in a Phase 1 trial evaluating PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine, or DHE. PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine. The Phase 1 study design is a double-dummy, double-blinded trial to assess the safety, tolerability, and pharmacokinetics of 3 doses of single doses of inhaled PUR3100 with IV placebo, as compared to IV DHE with inhaled placebo. Twenty-four healthy volunteers are to be randomized to one of the four dose groups consisting of six subjects each.

09:03 EDT Y-mAbs Therapeutics announces clearance of IND for GD2-SADA - Y-mAbs Therapeutics announced initiation of its first clinical trial with a SADA construct. This Phase 1 multicenter basket trial targets malignant melanoma, sarcoma and small cell lung cancer. The trial will have three parts: Part A with dose-finding for the SADA molecule and testing of dosing intervals between the protein and the 177Lu-DOTA payload, Part B will determine the optimal dose of 177Lu-DOTA, and Part C will be evaluating safety and initial signals of efficacy using repeated dosing. The Company expects a total of approximately 59 patients at 6-10 U.S. sites to be included in the trial. "The FDA acceptance of the IND for GD2-SADA marks an important milestone towards our mission of developing novel SADA treatments as we continue to execute our clinical development strategy for our pipeline of SADA constructs for the treatment of cancers with unmet medical need," said Thomas Gad, founder, President and Interim CEO. "We are seeing significant partnership interest for the SADA technology and we believe we are well-positioned to leverage the SADA platform as we move forward. We are truly excited about the potential of the SADA technology, which has already shown great promise, and we believe that it can further unlock the potential of radiolabeled therapeutics in tumors that have not historically demonstrated meaningful responses to radiolabeled agents."

09:03 EDT FDA grants Breakthrough Device Designation to Abbott's DBS system - Abbott announced that the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation, or DBS, system in treatment-resistant depression, or TRD, a form of major depressive disorder, or MDD. Breakthrough Device Designation expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions. Abbott's DBS system is a personalized, adjustable therapy that involves implanting thin wires into targeted areas of the brain. A pulse generator implanted under the skin in the chest is connected to the leads and produces electrical impulses that can modulate abnormal brain activity.

09:02 EDT ZoomInfo hires Bryan Law as chief marketing officer - ZoomInfo (ZI) announced that it has hired Bryan Law as chief marketing officer. Law will lead ZoomInfo's marketing organization and will prioritize driving demand and supporting company growth, enhancing ZoomInfo's brand awareness, and expanding ZoomInfo's thought leadership. Most recently, he served as senior VP, marketing and general manager of e-commerce at Salesforce (CRM).

09:02 EDT Equinor acquires battery storage developer East Point Energy - Equinor said has signed an agreement to buy a 100% stake in the U.S. based battery storage developer East Point Energy. "The acquisition supports Equinor's ambition to be a leading company in the energy transition and provides a platform for broadening our energy offerings in the US," the company said in a statement. The privately-owned East Point Energy is headquartered in Charlottesville, Virginia and has a 4.1 GW current pipeline of early to mid-stage battery storage projects focused on the East Coast. Additional growth potential beyond the current pipeline has been identified, Equinor noted. The transaction agreements were signed on July 9 and the transaction is planned to be completed in Q3. Reference Link

08:55 EDT Altamira Therapeutics announces publication of RNA delivery platform data - Altamira Therapeutics announced the publication of a peer-reviewed article in the scientific journal Biomaterials Advances titled, "Peptide-siRNA nanoparticles targeting NF-B p50 mitigate experimental abdominal aortic aneurysm progression and rupture" that covers a study conducted by a research group at Washington University, St. Louis. The study identified the NF-B p50 and p65 subunits as key modulators of the inflammatory process contributing to the development of AAA. The knockdown of NF-B subunits using siRNA delivered by Altamira's peptide-based nanoparticles was shown to mitigate aneurysm progression and rupture in two different experimental models. Since the p50 knockdown was more effective at preventing rupture, the article discussed that p50 represents a preferable target for rational drug design in AAA treatment since it lacks a transactivating domain and its knockdown may carry less risk of adverse effects.

08:52 EDT Evolus completes patient enrollment in Jeuveau study - Evolus has completed patient enrollment in its clinical study evaluating an "extra-strength" dose for extended duration of Jeuveau, its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics.

08:49 EDT Recruiter.com announces results of Recruiter Index for June - Recruiter.com Group has released the results of Recruiter.com's Recruiter Index for June 2022. After a dip in May, candidate sentiment, the measure of how open candidates are to new jobs, moved down. Recruiter sentiment, the measure of how recruiters feel about the job market, decreased to 3.2/5 this month, matching February 2022 levels. The decreases in both sentiments may result from a slight slow up in hiring. On average, recruiters worked on 16 open roles this month, down from 22 open positions in May. On average, when asked how many jobs candidates have had over the past two years, 44 percent of recruiters said candidates have had two jobs. This month, we saw an increase in the number of candidates who have had three and four jobs. Compensation is the only priority that ranked above remote work in June's Recruiter Index, at 42 percent this month. Not only did compensation claim the number one spot, but it is also the number one reason employees are leaving their current jobs as well. In-person roles are dominant over hybrid and fully remote roles this month. Remote positions have decreased by 56 percent since January.

08:47 EDT Rubicon announces nomination of Jack Selby to board of directors - Rubicon Technologies (RBT), announced the nomination of Jack Selby, Managing Director at Thiel Capital and former Senior Vice President & Corporate Officer at PayPal, to its Board of Directors upon the closing of the Company's previously announced business combination with Founder SPAC (FOUN).

08:44 EDT Viveve announces expansion of IP portfolio with patent issuance in Taiwan - Viveve Medical announced that the Taiwan Intellectual Property Office recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets. In Taiwan, the Viveve System is indicated for use in general surgical procedures for anticoagulation and hemostasis. Dynamic Medical Technologies, Inc. remains Viveve's exclusive distribution partner in the country.

08:42 EDT Minim announces launch of Motorola Q11 - Minim announced the launch of the Motorola Q11, a new WiFi 6 mesh system that delivers the most powerful wireless performance of the company's intelligent networking devices to-date. The first AX3000 entry to the full portfolio of Motorola networking devices provides access to blazing-fast gigabit speeds, perfect for daily home networking needs from remote work and 4K streaming, to multi-user gaming and more. The Motorola Q11 is currently available on MotorolaNetwork.com, Amazon.com and Walmart.com, and will be available on BestBuy.com in the coming weeks.

08:41 EDT AgEagle says FAA data confirms eBee as most used fixed wing sUAS - AgEagle Aerial Systems announced that the Federal Aviation Administration's commercial drone registration data confirms that the Company's eBee is the most used fixed wing small Unmanned Aerial System in the United States, accounting for 41% of all commercial fixed-wing drone registrations in the nation since 2016. According to the Company's analysis of official FAA Part 107 commercial drone registration data supplied to AgEagle pursuant to its FOIA Request submission, from 2016 - 2021, the eBee was the commercial sUAS of choice for U.S. commercial drone operators, outnumbering all other fixed wing drones registered, including Vertical Take-off and Landing aircraft, by a large margin as reflected in the table.

08:41 EDT Viveve announces expansion of IP portfolio with patent issuance in Taiwan - Viveve Medical announced that the Taiwan Intellectual Property Office ,TIPO,recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets."This most recent patent decision represents an important advance in our IP position because Taiwan is a key international market for our technology and plays an important role in influencing women's medical and health trends throughout Asia," said Scott Durbin, Viveve's chief executive officer. "With our robust and growing intellectual property estate, we continue to advance our global clinical development and commercialization strategy toward a potential new indication in the U.S. for the treatment of stress urinary incontinence in women."In Taiwan, the Viveve( System is indicated for use in general surgical procedures for anticoagulation and hemostasis. Dynamic Medical Technologies, Inc. remains Viveve's exclusive distribution partner in the country.

08:39 EDT XPEL picked as supplier to Rivian Automotive for factory direct program - XPEL (XPEL) announced that they have been selected as the exclusive supplier to Rivian Automotive (RIVN) for their new paint protection film factory direct program. By the terms of the agreement, Rivian Automotive will offer factory direct PPF options to its customers ordering their new R1T and R1S models beginning late 2022. Customers will be able to choose between two PPF option packages: Front Gloss Paint Guard or Full Body Satin Paint Guard. The Paint Guard packages have been developed cooperatively between XPEL and Rivian's vehicle engineering and design teams to enhance the adventures of R1T and R1S owners. XPEL will operate an installation facility in close proximity to Rivian's Normal, Illinois assembly plant, to ensure installation quality control. "We're pleased to have this opportunity to bring our proprietary design methodology and state-of-the-art paint protection films to Rivian customers as the exclusive supplier of factory direct PPF for their R1T and R1S vehicles," commented Tim Hartt, Vice President - Technical Operations & OEM of XPEL. "We are the leader in advanced OEM level PPF solutions and we look forward to leveraging our experience as a tier 1 supplier working with premium automotive brands, to introduce XPEL products to Rivian and their customers."

08:38 EDT Bioventus completes acquisition of CartiHeal - Bioventus announced that it has completed its acquisition of CartiHeal. "We are excited to add CartiHeal to our diverse portfolio of active healing solutions," commented Ken Reali, Bioventus' chief executive officer. "CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant medium- and long-term potential as evidenced by the robust data generated from its pivotal clinical trial showing superiority to current treatments. We believe that the addition of CartiHeal will complement our joint preservation technologies and specifically our HA business, further supporting our short- and mid-term growth drivers and helping us to deliver on our goal of sustained double-digit revenue growth. We welcome the CartiHeal team to Bioventus and look forward to bringing this life-improving technology to as many patients as possible."

08:37 EDT Soluna Holdings engages MZ Group to lead strategic investor relations program - Soluna Holdings, the parent company of Soluna Computing, has engaged international investor relations specialists MZ Group, MZ, to lead its comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with SLNH's management to build upon existing investor relations and shareholder communications designed to increase the Company's visibility throughout the investment community. Michael Toporek, CEO of Soluna Holdings, stated, "We continue to execute on an ambitious plan to grow within this industry and strategically position our company. As we expand our offering beyond cryptocurrency to batchable computing for machine learning, natural language processing, and scientific computing, we believe that having MZ as a partner will help us clearly communicate our message to the broader investment community. We look forward to working with the entire team at MZ Group to communicate the multiple avenues to drive growth and build long-term value for our shareholders."

08:36 EDT Lincoln Educational to launch hands-on training courses at Kindig Academt - Lincoln Educational Services will launch a new series of introductory hands-on training courses at the Kindig Academy at Lincoln Tech in Denver. The shorter weekend courses will complement the school's comprehensive six-week Custom Design and Fabrication program by offering "no experience necessary" classes for students interested in building skills for the automotive customization and repair industries starting July 23rd.

08:35 EDT Processa Pharmaceuticals to present at World Orphan Drug Congress USA - Processa Pharmaceuticals announced that Dr. David Young, it's CEO, will present "Thinking Regulatory First - Considerations for the Effective Development of Rare Disease Therapies" at the World Orphan Drug Congress USA 2022 Conference on Wednesday, July 13, 2022 at 3:25 pm EDT. Although Processa has a pipeline of 5 drugs, 3 of which have FDA Orphan Designation, we are only developing 2 for the treatment of an orphan indication. PCS499 is being developed for the treatment of the serious orphan indication, ulcerative Necrobiosis Lipoidica, and PCS3117 is being developed for the treatment of pancreatic cancer. PCS499 is currently in Phase 2B trial given that some efficacy has already been demonstrated in a proof-of-concept Phase 2A trial. The enrollment of the interim analysis cohort within the Phase 2B trial should be completed over the next few months with the analysis of this interim cohort of patients occurring in the 1H of 2023. The study is expected to complete enrollment by the end of 2022. Currently, there are no FDA approved drugs for uNL or NL and the drugs used off-label do not provide adequate treatment benefits while having adverse events profiles that minimize their use. PCS3117 has an IND in pancreatic cancer and Phase 2A data demonstrating efficacy in various targeted pancreatic cancer patients. Processa is presently designing the potential development programs and will determine which has the greatest chance of FDA approval after meeting with the FDA at the end of 2022. Positioning PCS3117 as 1st, 2nd or 3rd line therapy will not only be important for approval but also for commercialization.

08:34 EDT Bridgeline Digital announces Celebros chosen by PharmaDirect - Bridgeline Digital announced that their natural language processing and artificial intelligence search tool, Celebros, has been chosen by PharmaDirect to power its on-site search. PharmaDirect has selected Celebros to implement its site search solution across its site on the AB Commerce platform to provide a modern experience for its customers. "Our new partner has been in the pharmaceutical industry for decades, and we are excited to be able to aid in their continued success by providing tools to better their customers' journey," says Ari Kahn, CEO of Bridgeline. "I look forward to seeing how Celebros will help them grow their revenue strategy."

08:33 EDT Allogene Therapeutics appoints Stephen Mayo to board of directors - Allogene Therapeutics announced the appointment of Stephen Mayo, Ph.D., to the company's Board of Directors. Dr. Mayo is the Bren Professor of Biology and Chemistry and Merkin Institute Professor at the California Institute of Technology in Pasadena, California. He served as Vice Provost for Research at Caltech from 2007 to 2010 and Chair of its Division of Biology and Biological Engineering from 2010 to 2020.

08:33 EDT The Very Good Food Company appoints Pratik Patel as CFO - The Very Good Food Company announced the appointment of a new CFO Pratik Patel. Pratik will commence employment as CFO of VERY GOOD on July 25. He has over fifteen years of experience as a senior accounting and finance professional, with expertise in integration and external reporting. Prior to joining VERY GOOD, Pratik was Head of Finance at Bardel Entertainment, a Canadian animation studio. Before joining Bardel in 2017 as Controller, he held several senior level accounting and finance positions, most recently with WildBrain, a publicly traded family entertainment company where he oversaw financial and disclosure reporting throughout the Company's merger integration of Nerd Corps Entertainment and Studio B.

08:32 EDT Milestone Scientific announces F&M Feed as exclusive distributor in Greece - Milestone Scientifiy signed an exclusive distribution agreement in Greece for the CompuFlo Epidural System with F&M Feed. In connection with the agreement, Milestone Scientific has commenced sales and shipments of its CompuFlo Epidural Instrument and consumables to Greece.

08:31 EDT Edible Garden announces expanded distribution of its hydro basil - Edible Garden AG announced the expanded distribution of its sustainable, hydro basil with a major northeast retailer, across their more than 350 locations. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are pleased to announce this expanded distribution of our sustainable, hydro basil with a major northeast retailer, which has agreed to carry the product in all their more than 350 locations across the northeast. This represents an important expansion of our geographic footprint for hydro basil, as well as further validation of our growing consumer appeal. With the world's growing population placing an increasing burden on our environment and food supply, we believe it is our duty to utilize responsible and sustainable farming solutions. Edible Garden uses advanced hydroponic farming methods to provide customers with the highest quality products, free from harmful pesticides and herbicides, residues, or contaminants. The utilization of our hydroponic greenhouse, combined with vertical growing techniques, allows us to maximize product yields in a sustainable manner. Moreover, we avoid depleting natural resources through the use of renewable and proprietary packaging materials that preserve freshness, reduce spoilage and lower costs. This packaging includes a fully sustainable hydro basil tray, a recyclable and biodegradable pot, and a recyclable carboard carrier tray. We are effectively executing on our expansion strategy and look forward to both expanding our SKUs within this major retailer, as well as announcing additional retailers to our growing network."

08:30 EDT U.S. Gold receives assays for last three holes of CK Gold Project 2021 - U.S. Gold reported that it has received assays for the last three holes of its CK Gold Project 2021 drilling program. The Company continues to be encouraged by the positive results from its confirmatory and expansion drilling. Additionally, in June 2022, internationally geologist Richard Sillitoe reviewed the core, consulted with Company geologists and conducted a site visit of the Project. Following the visit, Sillitoe confirmed that the gold-copper mineralization is of porphyry type and may have expansion opportunities at depth, to the southeast and in other, yet to be discovered, porphyry intrusions since deposits of this type can occur in clusters. In commenting on these latest assay results and Sillitoe's visit, Kevin Francis, Exploration and Technical Services of U.S. Gold, said, "The primary purpose of the 2021 drilling program was to support feasibility study level hydrology and geotechnical studies. The three holes reported, CK21-04c, CK21-05c and CK21-08c, were primarily hydrology holes. CK21-04c confirms results of additional 2021 drilling which intercepted future mineral resource expansion potential immediately south and below the proposed open pit. While we know that there are additional mineral resources requiring further exploration expenditures, our priority is to realize the value of the commercially attractive gold-copper project identified in our prefeasibility study, published December 1, 2021." The Company is reporting results from 3 core holes completed during the 2021 drilling program. Gold and copper assays from the 2021 program continue to extend mineralization beyond the prefeasibility mineral resource estimate. As such, the Company believes that an increase of mineral resources is likely.

08:24 EDT Post Holdings announces early tender results of cash tender offer - Post Holdings announced that as of 5:00 p.m., New York City time, on July 11, 2022, pursuant to and in accordance with its previously announced cash tender offer, approximately $1,449 million in aggregate principal amount of the Company's notes had been validly tendered and not validly withdrawn on or prior to the Early Participation Date, which, if and when accepted for purchase by the Company pursuant to the terms and conditions of the Tender Offer, would result in aggregate Total Consideration of approximately $450 million, which Total Consideration was determined in accordance with the terms of the Tender Offer based on the principal amounts of Notes tendered and the Bid Premiums at which such tenders were made.

08:21 EDT Alignment Healthcare to begin offering Alignment Health Plan in Florida - Alignment Healthcare will begin offering Alignment Health Plan benefit packages for the first time in Florida in 2023, reaching nearly 500,000 Medicare-eligible adults across four counties in the state, pending regulatory approval from the Centers for Medicare & Medicaid Services. Alignment plans to offer HMO, chronic condition and dual-eligible special needs plan options in Clay, Duval, Manatee and Sarasota counties for coverage starting Jan. 1, 2023. In addition, if approved, eligible beneficiaries would have access to popular Alignment Health Plan benefits such as non-emergency transportation, virtual exercise classes and grocery benefits as well as enable them to take advantage of the company's 24/7 ACCESS On-Demand Concierge service. Along with Florida, the company also announced its expansion into 10 additional counties across Arizona, California, Nevada, North Carolina and Texas in 2023, subject to approval by CMS.

08:19 EDT MaxCyte signs strategic platform with LG Chem - MaxCyte announces the signing of a strategic platform license, SPL, with LG Chem, a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science. Under the terms of the agreement, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue. Doug Doerfler, President and CEO of MaxCyte, said: "We are thrilled to partner with the global multinational company LG Chem to support their CAR T programs for solid tumors. This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer."

08:16 EDT Metals Company contracts CSIRO-led consortium - The Metals Company announced that its Australian subsidiary, The Metals Company Australia, has entered into a research funding agreement with a consortium of institutions led by Australia's Commonwealth Scientific Industrial Research Organisation, CSIRO, to create a framework for the development of an ecosystem-based management and monitoring plan, EMMP, for its proposed deep-sea polymetallic nodule collection operations in the Clarion Clipperton Zone, CCZ, of the Pacific Ocean. The CSIRO-led consortium, which includes global leaders in the development and application of effective EMMPs in a diversity of marine areas, will leverage TMC's extensive environmental baseline data - acquired in the Company's NORI project area in the CCZ - to help develop appropriate indicators and tolerance limits to create safe parameters for collecting seafloor nodules. Gerard Barron, Chairman and CEO of The Metals Company, said: "Last year our subsidiary, NORI, completed environmental baseline studies in partnership with leading marine research institutions. We've now got one of the world's most extensive deep-sea datasets to hand over to the CSIRO-led consortium, experts with the practical experience we need to develop a scientifically robust framework for a marine ecosystem-based management program for NORI-D. I'm thrilled that these trusted and independent institutions have agreed to undertake this research, setting a high bar for future work in this industry."

08:15 EDT Indonesia Energy discovers potential natural gas reservoir - Indonesia Energy announced that while drilling the Kruh 28 well on IEC's Kruh block, IEC unexpectedly found evidence of a potential natural gas bearing reservoir between 976 and 1,006 feet interval with 25 feet net thickness. This initial evidence was supported by both wireline logging and geologic logging data. This gas zone was not encountered in previous oil wells where IEC announced only oil discoveries. IEC is continuing to drill the well towards the expected oil zone at 2,836 to 2,964 feet and expects to report final results when the well is anticipated to be completed in the coming weeks. Frank Ingriselli, IEC's President, commented "We are certainly very excited about encountering this gas zone in the Kruh 28 well which, if fully confirmed, could provide significant upside to our plans to develop the Kruh Block, where our new wells at the current price of oil are expected to have net revenues in their first 12 months that is more than 150% of the cost to drill such well. This potential gas discovery reinforces our belief that the Kruh Block is a world class asset. Moreover, achieving cash flow positive operations has been an important goal for our company, and we are pleased to be able to take advantage of prevailing oil prices to reach this juncture. Obviously oil prices are subject to volatility, but if the current high prices for oil are sustained as we move forward, we believe we will have the potential to grow our cash flow as new wells from our Kruh Block drilling program begin to produce. Additionally, we are moving forward to aggressively set the stage to develop our potential billion-barrel equivalent natural gas Citarum Block, where the previous operator drilled a few gas discoveries" concluded Ingriselli.

08:14 EDT Cybin begins trial enrollment for CYB003 study for MDD treatment - Clinilabs Drug Development Corporation announced that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder MDD. CYB003 is being developed by Cybin , a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics ". Cybin announced that it received Investigational New Drug clearance from the U.S. Food and Drug Administration for the Phase 1/2a trial at the end of June, marking the industry's first novel psilocybin analog to enter clinical development. "Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003," said Jeanine Falinski, Vice President of Strategy and Corporate Development at Clinilabs. "We are excited by the potential of these therapeutics and hope that the future is life-changing for individuals suffering from mental illness. We are encouraged by the interest from potential research participants who have already come forward prior to today." "Successful patient recruitment and a proper clinical environment are integral components of this trial. As a global leader in drug development services, Clinilabs is a perfect partner and we are thankful for their support and guidance," said Doug Drysdale, Chief Executive Officer of Cybin.

08:12 EDT In8bio appoints LaMontagne as SVP, Business Development - IN8bio announced an appointment to its executive team to lead the Company's business development efforts. Kenneth LaMontagne, Ph.D., joins the company as Senior Vice President, SVP, Business Development, to advance the company's partnership strategy and execute collaborative transactions to promote growth. Prior to joining IN8bio, Dr. LaMontagne was a Vice President in Business Development at Artisan Bio, a cell engineering company developing next-generation cellular therapies.

08:09 EDT Provident Financial announces $475,000 in NRTC funding awards - Provident Bank announced the Bank has awarded $475,000 in funding to five non-profit organizations as part of the New Jersey Department of Community Affairs, Neighborhood Revitalization Tax Credit Program for fiscal year 2022. The nonprofit organizations will use the funding to implement revitalization plans that address housing and economic development, provide opportunities for entrepreneurs to start businesses and job training for local residents, as well as complementary activities such as social services, recreation activities, and open space improvements. The New Jersey Department of Community Affairs served as the intermediary agency between the non-profit organizations and Provident Bank.

08:08 EDT Moving iMage, Alamo Drafthouse Cinemas in pact for Barco SP4k projectors - Moving iMage Technologies announced an exclusive three-year purchase agreement with Alamo Drafthouse Cinemas for Barco SP4k laser projectors for both new theaters and existing technology upgrades. "We are excited to announce this exclusive relationship with Alamo Drafthouse, one of our long-standing partners," said Jerry Van de Rydt, senior vice president of FF&E sales at MiT. "The industry is in the early stages of a multi-year technology upgrade cycle, and the Barco SP4k laser projector is a great way to enhance the moviegoer experience through its improved picture contrast, maximum picture brightness and vivid colors, all of which are on-screen benefits of Barco technology." "Alamo is excited about this next generation of 4k laser projection technology to bring our guests the very best presentations available," said Frankie Vaquerano, director of presentation for Alamo Drafthouse Cinema. "These projector upgrades also come with lamp and power operational savings that will benefit Alamo for many years to come." The SP4k models of the Barco Series 4 family bring native 4K resolution, higher contrast and enhanced uniformity into the movie theater. The Barco Active Image Management includes patented technology to guarantee sharp, consistent image quality over time.

08:08 EDT Agile Therapeutics narrows Q2 Twirla demand view to 21K-21.5K cycles - Previous view 20K-22K cycles. The updated Twirla demand guidance reflects continued progress made in both the retail and non-retail channels, with the non-retail channel showing significant quarter over quarter growth via the Company's partnership with Afaxys. Additionally, the Company previously guided OPEX for the second quarter 2022 to be in the range of $12.5 million to $13.5 million and now believes OPEX will be below the low end of the previously guided range. The Company expects OPEX will be in the range of $11.5 million to $12.5 million, with the change primarily attributable to optimization of the Twirla sales force and marketing efforts to better focus on the most productive territories with high volume and favorable third-party reimbursement as well as the optimization of expense across all general and administrative areas.

08:06 EDT Porch Group's HOA reaches national expansion milestone - Porch Group's Homeowners of America, HOA, a property and casualty insurance provider, announced the milestone launch of homeowners insurance services in Indiana, marking its 20th state of operation. "We are expanding our homeowners insurance products nationwide, allowing us to take full advantage of our vertical software platform," said Matt Ehrlichman, Porch founder, chairman, and CEO. "The introduction of services in Indiana continues our momentum as we continue to generate next-level service for homeowners and HOA agents."

08:06 EDT Markforged to acquire Digital Metal - Markforged announced that it has entered into a definitive agreement with Hoganas AB to acquire Digital Metal, the creator of a binder jetting solution, extending Markforged's capabilities into high-throughput production of metal additive parts. With this new offering, manufacturers have the opportunity to produce high volumes of functional metal parts with minimal setup required. As part of the transaction, Markforged will pay Hoganas approximately $32M in cash, approximately 4.1M shares of Markforged common stock and approximately $1.5M in cash to settle certain intercompany balances, subject to certain adjustments. The acquisition of Digital Metal is expected to close during the third quarter of 2022, subject to customary conditions.

08:05 EDT scPharmaceuticals announces results from AT HOME-HF Phase 2 pilot study - scPharmaceuticals announced positive results from the AT HOME-HF Pilot study, a Phase 2, multicenter, randomized study that compared scPharmaceuticals' investigational product, FUROSCIX, with a "treatment as usual" approach in chronic heart failure patients presenting to a heart failure clinic with worsening congestion and requiring augmented diuresis. The study enrolled 51 subjects, of which 34 received FUROSCIX and 17 received "treatment as usual." Data highlights: There was a positive trend in the Finkelstein-Schoenfeld win ratio of the hierarchal primary composite endpoint consisting of cardiovascular death, heart failure hospitalizations, emergency department visits for heart failure and % change from baseline of NT-proBNP at day seven in the FUROSCIX group compared to the "treatment as usual" group across multiple analysis populations. Subjects randomized to FUROSCIX had a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to "treatment as usual" at day 30. All pre-defined secondary endpoints measuring symptoms of congestion, quality of life and functional status favored the FUROSCIX group and included a two kilogram greater weight loss at day three and a 12-point increase in the 12 item Kansas City Cardiomyopathy Questionnaire summary scores at day 7 and day 30. There were 11 subjects that experienced 21 adverse events during the 30-day study period that were determined by the investigator to be related to FUROSCIX. The most common related adverse event was infusion site pain that was mild in severity. There was one serious adverse event that was assessed by the investigator as possibly related to FUROSCIX, which resolved. During the 30-day study period, there was one death in the FUROSCIX group which occurred on study day 30 and was assessed by the investigator to be not related to FUROSCIX.

08:04 EDT Applied UV granted patents for device sterilizing ATM surfaces - Applied UV announces that its wholly owned subsidiary SteriLumen has been notified that the US Patent and Trademark Office USPTO has granted the patent pertaining to a system to neutralize pathogens on ATM surfaces. On a daily basis, consumers globally interact with numerous surfaces that need to be touched during normal uses, including ATMs with keyboards and interactive touch screens. As an example, according to the Company's internal research, as of 2018, there were approximately 470,000 ATMs in the U.S. alone. These surfaces are touched daily by an inordinate number of people that can harbor and transfer pathogens highly associated with illnesses and diseases. E.coli, salmonella and Staphylococcus aureus can be found on these commonly used surfaces and can easily spread to those in the general public if untreated; these bacteria and viruses can be transferred easily to cause serious illness. Banks are reducing the threat of litigation risk by incorporating the use of the best science available to protect consumers from contracting serious illnesses due to deadly surface pathogens found on ATMs.

08:03 EDT ProKidney, Social Capital Suvretta complete business combination - ProKidney and Social Capital Suvretta Holdings Corp. III completed their previously announced business combination. The newly formed company is named ProKidney Corp. and its Class A ordinary shares will commence trading on the Nasdaq Capital Marketunder the symbol "PROK" on July 12, 2022. The business combination was approved by SCS's shareholders at an extraordinary meeting held on July 11, 2022. ProKidney intends to use the proceeds received from the transaction to continue accelerating the development of its lead autologous cell therapy candidate, REACT, which is currently being evaluated in multiple Phase 2 and 3 clinical trials as a treatment for late-stage diabetic CKD approaching kidney failure. Based on clinical data generated to date, ProKidney believes that REACT has the potential to not only slow the progression of CKD, but in some cases to drive meaningful improvement in kidney function in patients with late-stage CKD - a groundbreaking first for CKD therapies that may delay or possibly prevent the need for dialysis in these patients. A cell therapy produced from a patient's own kidney cells, REACT comprises a proprietary mixture of progenitor cells that are grown, purified, and then placed back into the patient's kidney. This minimally invasive procedure, which begins with a standard biopsy, injects cells that harness the body's intrinsic ability to repair and restore damaged kidney tissue. The injection procedure has been shown to be better tolerated than contemporary biopsy and can be done repeatedly in one or both kidneys based on multiple Phase 2 trial findings. ProKidney's patented REACT therapy is the outcome of almost 20 years of development by ProKidney and its predecessors and is part of its broad-based intellectual property strategy. The company has filed more than 200 patents worldwide for its product, cell admixture, and manufacturing and quality processes. ProKidney's management team, led by founder and CEO Tim Bertram, brings over 200 years of combined experience in the discovery, development, manufacture, and commercialization of biotechnology, pharmaceutical, and device products. ProKidney is also led by an experienced board, chaired by Pablo Legorreta, founder and CEO of Royalty Pharma, the world's largest publicly listed acquirer of pharmaceutical royalty streams, bringing broad financial and scientific expertise with his successful track record in biopharma development and investing. The ProKidney board of directors also includes Dr. Brian Pereira, President and CEO of Visterra, Inc., former president and board member of the National Kidney Foundation and former editor of the widely read textbook "Chronic Kidney Disease, Dialysis, and Transplantation"; Dr. John M. Maraganore, founding Chief Executive Officer of Alnylam Pharmaceuticals, Inc.; William Doyle, founder and Chairman of Novocure; Dr. Alan Lotvin, M.D., Executive Vice President of CVS Health and President of CVS Caremark, CVS Health's pharmacy benefits manager; Dr. Uma Sinha, Chief Scientific Officer at BridgeBio Pharma; Jennifer Fox, Chief Financial Officer of Nuvation Bio; and Jose Ignacio Jimenez Santos, Chief Executive Officer of Grupo Financiero Inbursa. As a result of the business combination, ProKidney has received approximately $597 million prior to transaction-related expenses, including approximately $20 million held in SCS's trust account with the remaining amount from PIPE investors, which includes $125 million from Social Capital and an additional $50 million from existing ProKidney investors. The Company expects that the proceeds from the transaction will be sufficient to fund operations through data from its ongoing Phase 3 study of REACT in diabetic CKD.

08:03 EDT ZimVie announces positive policy decision from Anthem for AVBT - ZimVie (ZIMV) announced that Anthem Blue Cross Blue Shield, BCBS, a subsidiary/operating company of Elevance Health (ELV), has issued a positive medical policy decision applicable to anterior vertebral body tethering, AVBT, effective July 6, 2022. The decision expands potential treatment eligibility to patients indicated for AVBT within the 30+ million members covered under Anthem BCBS, and outlines the medical necessity criteria that must be met for coverage of AVBT. "This decision marks a significant win for Anthem BCBS patients and the broader pediatric scoliosis community," said Rebecca Whitney, SVP and President of ZimVie Spine. "Before the development of anterior vertebral body tethering, the primary surgical option for children with scoliosis was a spinal fusion with rigid rods that could limit mobility. The coverage decision from Anthem will provide children with greater access to AVBT as a motion preserving alternative that may allow them to return to their active daily lives. We hope that this decision also paves the way for policy updates from additional payers to positively impact the lives of children with scoliosis."

07:42 EDT MeaTech 3D signs memorandum of understanding with Umami Meats - MeaTech 3D is pleased to announce that it has signed a memorandum of understanding with Umami Meats for the joint development of 3D-printed cultured structured seafood. This collaboration opens a door for both companies into the Asian market, and Singapore specifically, which is currently the only country that has authorized the production and distribution of cultured meat. The agreement is part of MeaTech's strategy of collaboration with other players in the alternative protein space and takes advantage of the company's flexibility in its technological and biological capabilities to develop and print a wide variety of species. With this agreement, MeaTech will be adding seafood to its portfolio of bovine, avian and porcine products under development.

07:41 EDT Monarch Mining appoints Desormeaux to its board of directors - MONARCH MINING announces the appointment of Benoit Desormeaux as a director of the Corporation effective immediately. Benoit Desormeaux has over 12 years of board experience, including as audit committee chair, with public and private companies and charitable organizations.

07:38 EDT Step Energy amends, extends credit facility - STEP Energy Services provides an update on its credit agreement. STEP has entered into an agreement with a syndicate of Canadian banks which amends and extends its credit agreement. The principal terms of STEP's Third Amended and Restated Credit Agreement include: a C$215 million revolving facility, a C$15 million operating facility, a $15 million operating facility; and a three-year term with a maturity date of July 12, 2025. The financial covenants in the Credit Agreement are as follows: Funded Debt to EBITDA Ratio: not more than 3.00:1.00, calculated quarterly on the last day of each Fiscal Quarter on a rolling four quarter basis; and Interest Coverage Ratio: at least 3.00:1.00, calculated quarterly on the last day of each Fiscal Quarter on a rolling four quarter basis. The Company's banking syndicate is led by ATB Financial as Administrative Agent, Co-Lead Arranger and Co-Bookrunner and the Canadian Imperial Bank of Commerce as Syndication Agent, Co-Lead Arranger and Co-Bookrunner. The syndicate also includes the Bank of Montreal, the Bank of Nova Scotia, HSBC Bank Canada and the Toronto Dominion Bank, all of which were participants in the previous facility. Export Development Canada has exited STEP's syndicate. STEP will pay customary fees and expenses at prevailing market rates to the lending syndicate as a condition of the amendment.

07:38 EDT Designer Brands announces agreement with Le Tigre 360 Global - Designer Brands announced an investment in and licensing agreement with Le TIGRE 360 Global. This is another exciting step forward in the Company's growth as a brand builder and its plans to double sales of Owned Brands by 2026. Designer Brands adds Le TIGRE to the Company's portfolio of Owned Brands, which allows Designer Brands to develop and produce product and provides the Company a unique opportunity to share premium athletic product with its customers. The current portfolio of brands includes Vince Camuto, Reebok, Hush Puppies, Jessica Simpson, Crown Vintage, JLO Jennifer Lopez, Mix No. 6, Lucky Brand and Kelly & Katie.

07:37 EDT Madison Dearborn Partners to acquire majority stake in Unison from Carlyle - Unison, a provider of procurement, supply chain, and contract management software to U.S. federal government agencies and government contractors, announced that it will receive a strategic majority investment from funds affiliated with Madison Dearborn Partners As part of the transaction, funds managed by global investment firm Carlyle will sell its majority stake to MDP, while remaining a strategic partner as a minority investor. MDP joins existing investors, Carlyle and Unison management, to provide additional resources and industry expertise to help Unison continue to enhance its innovative software offerings and growth trajectory. Financial terms were not disclosed. "We are thrilled to welcome our new partners from MDP and look forward to their support as we continue to execute our strategy to provide innovative and reliable software solutions for federal organizations and government contractors," said Reid Jackson, CEO of Unison. "MDP brings a wealth of experience and additional financial resources that will allow Unison to accelerate our growth and deliver world-class software products to meet the evolving needs of our customers. MDP's track record of successful partnerships with vertical enterprise software, procurement and supply chain, and government services and techno. The transaction is anticipated to close in the third quarter of 2022. Upon closing, funds associated with MDP will own a controlling stake in Unison, while Carlyle will retain a significant minority equity position. Unison's management team will continue to serve in their current roles and members of Unison leadership will maintain a significant portion of their investment in Unison.

07:36 EDT Alithya Group signs anticipated $10M contract to assist Oracle client - Alithya Group (ALYA) is proud to announce the signing of a contract to accompany an existing Oracle (ORCL) client through important stages of its digital transformation processes. The contract has now commenced and is expected to generate approximately $10M USD in revenues over its 2.5-year term. The contract, signed with a client that offers dental insurance coverage to millions of Americans, covers an Oracle Cloud Enterprise Resource Planning project that will include the implementation of a payroll system, as well as change management and cloud-based training services to ensure optimal adoption of the technology. The newly signed contract follows a previous Oracle Cloud Enterprise Performance Management project conducted between the Alithya Oracle team and the client.

07:35 EDT Akanda to supply Tetra Bio-Pharma with pharmaceutical grade cannabis flower - Akanda and Tetra Bio-Pharma announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEFTM and related products. In addition, Akanda will act as a Contract Development and Manufacturing Organization for Tetra's clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in addition to being an EU GMP cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company, while Tetra secures a stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and commercialization.

07:33 EDT Lordstown Motors says Edward Hightower elected to additional role of CEO - Lordstown Motors announced several key executive appointments that further strengthen the company's senior leadership team. Daniel Ninivaggi was elected to serve as Executive Chairman of the Board of Lordstown Motors. In this role, Dan will focus on corporate strategy, strategic partnerships and capital raising. Edward Hightower, the company's President, has been elected to the additional role of CEO, effective immediately. Edward will also continue to serve as CEO of MIH EV Design LLC, LMC's product development joint venture with Foxconn. He has also been elected to the Board of Directors of Lordstown Motors. Dr. Donna Bell, a former Ford Motor Company executive with almost 30 years of automotive product development and technology innovation leadership experience, has been appointed Executive Vice President, Product Creation, Engineering and Supply Chain, effective immediately. Andrew Reyntjes, a 30-year veteran of the automotive and commercial fleet industry, was appointed Senior Vice President, Sales, Service and Marketing, effective June 29. Jill Coniglio-Kirk was appointed Vice President of People & Culture, effective June 20. Jill has more than 20 years of experience in automotive human resources roles and building out early-stage organizations. Jane Ritson-Parsons will be transitioning out of the role of Chief Commercial Officer and become an advisor to the company.

07:32 EDT Quotient, InfYnity Biomarkers partner to expand MosaiQ infectious disease menu - Quotient announced an agreement with InfYnity Biomarkers, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient's MosaiQ solution. Under the collaboration agreement, InfYnity Biomarkers will assist Quotient in the research and design of infectious disease assays to enrich and expand the MosaiQ Serology Disease Screening menu and reduce time and cost of development and commercialization. InfYnity is developing antibodies and antigens suitable for multiplexed infectious disease blood screening, confirmatory testing, determining vaccine efficacy, and monitoring testing that will be evaluated as part of the research collaboration.

07:16 EDT AerCap reports Q2 major transactions - AerCap Holdings has announced its major business transactions during the Q2: Signed 125 lease agreements, including 11 widebody aircraft, 43 narrowbody aircraft, 2 regional jets, 32 engines and 37 helicopters; Completed 16 purchases for 13 aircraft, 1 engine and 2 helicopters; Executed 43 sale transactions for 27 aircraft, 12 engines and 4 helicopters.

07:14 EDT Alta Equipment Group introduces dividend, $12.5M share repurchase program - Alta Equipment Group announced that its Board of Directors has initiated a regular quarterly common stock dividend of 5.7c per share, or approximately 23c per share on an annualized basis. The first dividend will be payable on August 31st, to shareholders of record as of August 15th. The Board also approved a $12.5M share repurchase program. "Over the last few months, we have been acutely focused on our capital allocation policy given the current market conditions and have consulted with numerous stakeholders. Since going public, we have executed on our strategy and demonstrated the ability to generate strong free cash flow in diverse economic and operating conditions. Based on these discussions, our belief in the flexibility of our business model, and the historical performance of our business and outlook, the Board approved these capital-related actions. While we believe strongly that the best use of the majority of our cash flows continues to be our accretive M&A pipeline, we also believe that the investments that we have made since going public have taken the business to a level where it is appropriate to provide a cash return to our valued shareholders. In addition to the dividend, the share repurchase program will provide us with a mechanism in place to purchase shares when the market value is trading at a discount to the Company's intrinsic value and where that market value is attractive relative to other uses of our cash flow," said Ryan Greenawalt, Chief Executive Officer of Alta. "We believe this is a very balanced and strategic approach to capital allocation, which allows us to maintain leverage at a reasonable level while continuing to pursue our growth strategy including accretive acquisitions and high-return organic opportunities. Our accretive M&A pipeline remains robust as evidenced by our entering into an agreement to acquire Yale Industrial Trucks, Inc. in Canada last week."

07:12 EDT React Gaming's Compete.gg granted API by Riot Games - React Gaming Group announced that its esports tournament platform, Compete.gg, has been granted access to the Riot Games API, allowing Compete to break into an entirely new realm of competitive esports with multiplayer online battle arena titles such as League of Legends, considered as one of the top-played games in the esports space. The API is a means to communicate between computer programs and will allow Compete to program its tournament platform to communicate directly with Riot so that League of Legends players, for example, can trust that their data and performance from matches they play on Compete are both accurate and reliable. As a result, Compete will leverage the Riot integration to offer a premium gaming experience by providing player profiles and seamless stats tracking. This next stage in Compete.gg's evolution highlights its user-focused vision and its constant push to improve its products and provides Compete.gg with an opportunity to set the standard for tournament experience in esports.

07:10 EDT Bicycle Therapeutics reports Genentech exercises option to initiate new program - Bicycle Therapeutics (BCYC) announced that Genentech, a member of Roche (RHHBY), has exercised its second option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets. Pursuant to the terms of the February 2020 agreement, Genentech was granted two collaboration expansion options, each of which gave Genentech the right to add one additional program to the collaboration in exchange for a $10M payment to Bicycle. In October 2021, Genentech exercised its first expansion option, and has now exercised its second expansion option, triggering an additional $10M payment. None of the compounds in Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration.

07:10 EDT XPO Logistics announces RXO as company name for planned spin-off - XPO Logistics announced that a new company identity has been created in connection with the planned spin-off of its tech-enabled brokerage platform. The spin-off is named RXO to reflect the company's commitment to provide reliability multiplied by outperformance. RXO will go to market with the tagline "Massive capacity. Cutting-edge technology." XPO unveiled the new company's identity on a landing page, RXO.com, where visitors can register to receive news about the spin-off's upcoming milestones and leadership appointments. As previously announced, XPO intends to separate its asset-based less-than-truckload business from its asset-light brokered transportation platform, creating two independent, publicly traded companies with vast growth prospects in North America. The spin-off's largest component will be truck brokerage, with complementary brokered services for managed transportation, last mile logistics and global forwarding. Usage of the RXO name, logo and other brand components will become effective upon the spin-off of RXO, Inc., which XPO expects to complete in the fourth quarter of 2022.

07:08 EDT Helius Medical announces online training for PoNS Therapy - Helius Medical Technologies announced the launch of its online training module for physical therapists seeking to treat gait deficit in adults with mild to moderate symptoms of multiple sclerosis.

07:07 EDT Societal CDMO amends license, supply agreement with Lannett - Societal CDMO announced that it has signed an amendment to its license and supply agreement with Lannett Company for the marketing of Verapamil PM and Verelan SR products. Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices. Additionally, the amendment awards Societal potential new GMP manufacturing agreements targeting injectable products for multiple additional Lannett development projects. "We immediately and aggressively undertook discussions with Lannett on a restructuring of our Verapamil PM and Verelan SR marketing agreement following the unexpected decline in sales that were reported during the first quarter. We were pleased with Lannett's willingness to work collaboratively to put an amendment in place that can benefit both parties and we look forward to continuing a positive relationship," said David Enloe, chief executive officer of Societal CDMO. "As part of our discussions with Lannett, it was important to Societal that we not only implement new terms that allow us to continue to achieve the desired financial results related to Verapamil PM product sales, but also to recognize further meaningful revenue opportunities through our relationship with the company. We believe that the amendment serves those purposes well and provides a pathway for Lannett and Societal to continue in a mutually beneficial partnership."

07:07 EDT Sutro Biopharma announces to host virtual research forum on iADCs - Sutro Biopharma announced that management will host a virtual research forum in which it will unveil the next product candidate, discuss immunostimulatory ADCs as a novel modality, and highlight recent enhancement to its cell-free manufacturing platform. Webcast details: Wednesday, July 20, 2022 at 4:30 pm ET, or 1:30 pm PT.

07:06 EDT Xos secures purchase order for 10 stepvans from Zeem Solutions - Xos announced it has secured a purchase order for 10 of its 100% battery-electric stepvans from Zeem Solutions, a fleet-as-a-service provider that builds and operates zero-emissions fleet depots, and has delivered the first vehicle to Zeem's Los Angeles-based depot during the second quarter of 2022. Zeem will offer Xos vehicles for lease as part of its fleet-as-a-service offering. "Zeem has created a first-of-its-kind suite of products for fleets and we're excited to partner with them on this journey," said Esther Santos, Director of North America Sales at Xos. "Xos and Zeem share a similar vision of decarbonizing transportation and supporting the growth of a clean energy economy, so this partnership is a natural fit."

07:05 EDT LoanDepot to cut workforce to 6,500 by year-end 2022 from 11,300 - LoanDepot states: "The Company is focused on aligning its cost structure for current and expected mortgage origination volumes. loanDepot is implementing a program expected to generate approximately $375 - $400 million of annualized savings by the end of 2022, through headcount reduction, attrition, business process optimization, reduced marketing and third-party spending, and real estate consolidation. Based on these savings, the Company continues to target a return to run-rate operating profitability exiting 2022. The implementation of Vision 2025 and actions taken earlier this year are expected to rightsize staffing levels from approximately 11,300 at year-end 2021 to approximately 6,500 by year-end 2022. Current headcount is 8,500 and severance and benefits-related payments of approximately $3.5 - $4.5 million are expected to be recorded in the second quarter of 2022. Other non-operating expenses expected to be incurred in the second quarter related to these efforts include approximately $2.0 million of real estate exit costs and approximately $2.5 - $3.0 million of outside service expenses. The Company expects to incur additional non-operating expenses during the second half of 2022 as part of the realignment of its cost structure, including severance and benefits-related charges currently anticipated between approximately $25.0 - $28.0 million, charges related to the exit of real estate between approximately $2.5 - $3.5 million and $7.0 to $9.0 million of outside service costs. As part of the Company's regular and ongoing reporting process, management determined it was necessary to complete an evaluation of its goodwill and intangible assets during the second quarter and recorded a non-cash impairment charge of $42.0 million as of June 30, 2022."

07:04 EDT Nuwellis initiates outpatient heart failure strategy using Aquadex therapy - Nuwellis announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure patients with Aquadex ultrafiltration in the outpatient setting - the first step toward commercializing this opportunity. The webinar featured perspectives from leading heart failure clinicians from across the U.S.: Ramesh Emani, MD, Interventional Heart Failure Cardiologist and Associate Professor of Clinical Medicine, Division of Cardiology, The Ohio State University -; Columbus, OH; Detlef Wencker, MD, Advanced Heart Failure Specialists - Dallas, TX; Pat Correlli, PA-C, Chief Outpatient Physician's Associate and Lead Clinician of Outpatient Congestive Heart Failure at MedStar Good Samaritan Hospital - Baltimore, MD. Panelists discussed the clinical and economic challenges associated with the current standards of care for managing fluid overload among heart failure patients, explored strategies for treating these patients in the outpatient setting, and shared their experiences with outpatient Aquadex UF therapy. Under the current standard of care, patients often have long hospital stays and hospitals are typically only partially reimbursed for the cost of care. Furthermore, hospitals receive no reimbursement for patients that are readmitted within 30 days of initial discharge. According to Premier Applied Sciences data, the average total unreimbursed cost per inpatient encounter is $24,027, which highlights the importance of reducing unscheduled 30-day readmissions. While reimbursement for ultrafiltration varies from state to state, panelists said, in their experience, reimbursement for the administration of Aquadex in the outpatient setting has been favorable for their hospitals. According to the panelists, heart failure patients with fluid overload are often caught in a cycle where they are hospitalized, inadequately decongested, sent home, and then rehospitalized when congestion issues resurface. In fact, national data suggests that 24% of these patients will be rehospitalized within 30 days of discharge, and 50% within 90 days. In a study conducted by Lin et al., investigators evaluated the impact of repeat HF hospitalizations on all-cause mortality and determined the risk variables related to patient mortality. They found that mean survival time was 2.6, 1.8, 1.5, and 1.3 years after the first, second, third, and fourth hospitalization, respectively, and concluded that repeat hospitalizations were a strong predictor of mortality for existing patients with HF1. The webinar panelists also shared how ultrafiltration with Aquadex therapy is being used in the outpatient setting to effectively address this challenge. According to Dr. Emani, ultrafiltration adequately decongests patients without significant injury to the kidneys, as evidenced by a reduction in unscheduled 30-day readmissions, significant weight loss, and stable serum creatinine levels in patients studied at The Ohio State University.

07:03 EDT Synlogic initiates Phase 1 study of SYNB1353 for treatment of HCU - Synlogic announced that it has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 designed to consume methionine for the potential treatment of homocystinuria, HCU. "We are delighted to continue to advance our pipeline of programs with today's announcement, a notable milestone as we continue towards three expected clinical readouts in 2022, and a reflection of the productivity of the Synthetic Biotic platform," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Given the particularly great need for new treatment options for those living with HCU, we look forward to sharing data from this study by the end of this year."

07:02 EDT Leap Therapeutics and BeiGene begin Part C of the DisTinGuish study - Leap Therapeutics (LPTX) and BeiGene (BGNE) announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-SSEDickkopf 1, or DKK1, antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer. Additionally, Leap is initiating a new company-sponsored trial of DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with colorectal cancer that is designed to expand into a randomized study. Leap is also supporting an investigator-initiated trial of DKN-01 plus pembrolizumab in patients with endometrial cancer to be conducted at The University of Texas M.D. Anderson Cancer Center and at the University of Alabama at Birmingham.

06:48 EDT Volta appoints Michelle Kley as Chief Legal Officer - Volta (VLTA) announced that its Board of Directors has further strengthened the company's Executive Team with the appointment of Michelle Kley as Executive Vice President, Chief Legal Officer, and Corporate Secretary, effective July 20, and William Cooper as Senior Vice President, Deputy General Counsel, and Assistant Secretary, effective on or before July 18. Kley most recently served as Executive Vice President, Chief Legal Officer, and Secretary at Virgin Galactic Holdings (SPCE), where she led all legal and compliance matters for the first publicly traded commercial human spaceflight company, including NYSE and SEC regulatory compliance, corporate governance, intellectual property, labor and employment matters, and litigation. Before that, Kley was Senior Vice President, Chief Legal and Compliance Officer, and Secretary of space technology company Maxar Technology (MAXR). Kley previously worked as an associate for Morrison & Foerster and Wilson Sonsini Goodrich & Rosati law firms. Kley received a J.D. degree from the University of California Berkeley Law School and graduated with a B.A. from Sonoma State University.

06:40 EDT Dollar General CEO Todd Vasos to retire, Jeffery Owen to succeed

06:35 EDT Hecla Mining reports Q2 preliminary production - Hecla Mining announced its preliminary production for the Q2. Highlights include: Silver production of 3.6M ounces, an increase of 10% over the Q1 due to record throughput at the Lucky Friday Mine; Gold production of 45,718 ounces, an increase of 10% over the first quarter, driven by better performance at the Casa Berardi mine; Zinc production increased 12% over the prior quarter; Lead production increased 23% due to increased production at Lucky Friday. "All three of Hecla's operating mines delivered solid performances during the second quarter, driven by expected increased silver production at Lucky Friday and gold production at Casa Berardi, while Greens Creek had a very solid and consistent quarter," said Phillips S. Baker, President and CEO. "Lucky Friday's silver production surpassed the 1-million-ounce mark for the quarter, totaling 1.2M ounces, a 38% increase over the previous quarter as we see the benefits to throughput resulting from the continuous improvement of the UCB mining method, and increasing grades. Casa Berardi's production increased by 10% over last quarter due to higher mill recoveries, grades, and throughput."

06:34 EDT Verve Therapeutics announces first patient has been dosed with VERVE-101 - Verve Therapeutics announced that the first patient has been dosed with VERVE-101, in its heart-1 clinical trial. VERVE-101 is a novel, investigational gene editing medicine developed by Verve and designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol. heart-1 is a global Phase 1b clinical trial that will evaluate VERVE-101 as a treatment for patients with heterozygous familial hypercholesterolemia, a prevalent and potentially life-threatening subtype of atherosclerotic cardiovascular disease. Interim clinical data for the heart-1 clinical trial including safety parameters, blood PCSK9 level and blood LDL-C level are expected in 2023.

06:33 EDT Peloton transitions to third party manufacturing in Taiwan - Peloton announced it is exiting all owned-manufacturing operations and expanding its current relationship with Taiwanese manufacturer Rexon Industrial. Rexon will become the primary manufacturer of the hardware for Peloton's iconic Bike and Tread product lines. Along with this expanded partnership, Peloton will be suspending operations at its Tonic Fitness Technology facility through the remainder of 2022. The company acquired Tonic in October 2019.

06:30 EDT Fortress and Insfrastructure approve details and timing of spin-off - Fortress Transportation and Infrastructure Investors announced that its Board of Directors has approved the details and timing of the spin-off of its infrastructure business. The spin-off will establish FTAI's infrastructure business as an independent, publicly traded company called FTAI Infrastructure. The spin-off will be effected as a distribution of all of the shares owned by FTAI of common stock of FTAI Infrastructure, a majority-owned subsidiary of FTAI, to the holders of FTAI common shares as of the record date. The distribution is expected to occur on August 1 subject to the conditions noted below, and the record date is July 21. It is expected that shares of FTAI Infrastructure common stock will begin trading on the Nasdaq under the ticker symbol "FIPWV" on a when-issued basis on July 20 subject to settlement after the distribution. Beginning on or about July 20, 2022, and through the distribution date of August 1, 2022, it is expected that there will be two ways to trade FTAI common shares - either with or without the distribution of FTAI Infrastructure common stock. FTAI shareholders who sell their FTAI common shares in the "regular-way" market after the record date and on or prior to the distribution date will be selling their right to receive shares of FTAI Infrastructure common stock in connection with the spin-off. Alternatively, FTAI shareholders who sell their FTAI common shares in the "ex-distribution" market during the same period under the symbol "FTAIV" will not be selling their right to receive shares of FTAI Infrastructure common stock in connection with the spin-off.

06:06 EDT KKR invests in 123Dentist, Altima Dental, and Lapointe Group merger - 123Dentist, Altima Dental, and Lapointe Group have entered into a merger agreement to create one of the largest dental support organizations in Canada, with nearly 350 supported dental practices. The transaction is being financed through equity capital provided by 123Dentist's existing financial partner, Peloton Capital Management; new investors KKR, and Heartland Dental, a KKR portfolio company and the leading dental support organization in the U.S.; and Sentinel Capital Partners, Altima Dental's existing financial partner. The transaction is subject to customary closing conditions, including clearance under the Competition Act, and is expected to close in the third quarter.

06:03 EDT Walmart to purchase 4,500 Canoo all-electric delivery vehicles - Walmart (WMT) has signed a definitive agreement with Canoo (GOEV) to purchase 4,500 all-electric delivery vehicles, beginning with the Lifestyle Delivery Vehicle, or LDV, with the option to purchase up to 10,000 units. The vehicles will be used to deliver online orders in a sustainable way which will also contribute to Walmart's goal to achieve zero-emissions by 2040. While the LDV is expected to begin hitting the road in 2023, the companies plan to kick-off advanced deliveries to refine and finalize vehicle configuration in the Dallas Fort Worth metroplex in the coming weeks. Canoo's electric vehicles will be driven by Walmart associates and used to deliver online orders, from groceries to general merchandise, as well as the potential to be used for Walmart GoLocal, the retailer's delivery-as-a-service business. Canoo anticipates starting production of the Lifestyle Delivery Vehicles beginning in Q4.

06:02 EDT Catalyst Pharmaceuticals settles patent infringement litigation with Jacobus - Catalyst Pharmaceuticals announced that it has settled its ongoing patent infringement litigation with Jacobus Pharmaceutical Company. Catalyst had asserted in its patent litigation that Jacobus and PANTHERx induced infringement by third parties of FIRDAPSE related patent rights in their marketing and distribution of Ruzurgi. As part of the settlement, Catalyst will dismiss all claims related to the patent litigation between the companies and has acquired certain of Jacobus' intellectual property rights, including the rights to develop and commercialize Ruzurgi in the U.S. and Mexico. Ruzurgi is not currently approved for distribution in the United States as a result of the FDA decision to convert the Ruzurgi approval for pediatric use to a tentative approval following a decision of the U.S. Circuit Court of Appeals for the 11th Circuit. The Appellate Court determined that the approval of the Jacobus NDA for Ruzurgi for pediatric patients violated Catalyst's orphan drug exclusivity for FIRDAPSE for the treatment of LEMS. Jacobus has also agreed to dismiss its pending Petition for a Writ of Certiorari before the U.S. Supreme Court seeking to overturn the 11th Circuit Court of Appeals decision. Pursuant to the terms of the settlement, Catalyst will make a cash payment to Jacobus plus pay Jacobus a low single digit royalty on Catalyst's U.S. net sales of amifampridine.

05:42 EDT FTC to crack down on illegal use, sharing of sensitive data by tech companies - The FTC on Monday warned the tech industry against using data-anonymization claims when it's not true, something that could be considered a deceptive trade practice. "Companies that make false claims about anonymization can expect to hear from the FTC," said Kristin Cohen, the acting associate director for the commission's privacy division, in a blog post. In the post, the FTC says it's committed to protecting consumers' privacy, including their reproductive health information. "We will vigorously enforce the law if we uncover illegal conduct that exploits Americans' location, health, or other sensitive data," Cohen wrote. "The next stop in the murky marketplace may be data aggregators and brokers - companies that collect information from multiple sources and then sell access to it (or analyses derived from it) to marketers, researchers, and even government agencies. These companies often build profiles about consumers and draw inferences about them based on the places they have visited. The amount of information they collect is staggering." Reference Link

05:15 EDT Juniper selected by Oil India Limited for data center, campus network upgrades - Juniper announced that they have been selected by Oil India Limited, the country's second largest state-owned oil and gas company, for upgrades to its data center and campus networks to support the company's sustainability goals and digital transformation journey that will contribute to India's vision of energy independence. With a flexible, high-performance Juniper IP fabric, Oil India will be able to automate key business and operational processes, increasing its business agility and creating more seamless experiences for its customers.

05:08 EDT Willis Towers Watson acquires Butterwire, terms undislosed - WTW announced the acquisition of Butterwire, a FinTech provider of data analytics, artificial intelligence, or AI, and machine learning platforms. Using these capabilities, WTW clients will be able to manage climate-related financial risks at scale and speed. Based in Glasgow, Scotland, the financial analytics company will become a part of WTW's Climate and Resilience Hub. Butterwire software already incorporates WTW's proprietary Climate Transition Value at Risk, or CTVAR, methodology, which quantifies the anticipated impact on equity and fixed-income valuations of aligning with the goals of the Paris Agreement..